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ABSTRACT  
 
The annual incidence rate of cancers of the central nervous system (CNS) is approximately 100 per 
million in the Northern European countries. CNS tumors are the most common solid tumors in the 
childhood. More than one half of malignant gliomas are eventually fatal. Gliomas, tumors of the glial 
cell origin, are the most common adult brain tumors. Gliomas are often divided into four malignancy 
grades, of which the grade four gliomas, glioblastomas, are the most aggressive ones. Glioblastomas 
are further divided into two categories, the primary and the secondary glioblastomas. Primary 
glioblastomas arise de novo without a pre-existing lesion, whereas secondary glioblastomas arise 
from a pre-existing lower grade astrocytic tumour. At present, there is no curative treatment available 
for glioblastoma. 
 
Gene amplification, a gene copy number increase at a specific region of a chromosomal locus, is one 
of the molecular mechanisms associated with tumour progression. In general, gene amplifications are 
more common in advanced, widely metastatic cancers as compared to local ones. Receptor tyrosine 
kinase gene aberrations, such as amplifications of EGFR and PDGFRA, are also implicated in the 
genesis of gliomas, as are mutations of some genes.  
 
The receptor tyrosine kinases KIT, PDGFRs and VEGFRs are currently important clinical targets for 
tyrosine kinase inhibitors. In the present study we investigated expression and amplification of KIT, 
PDGFRA, VEGFR2 and EGFR in glioblastomas and in lower grade gliomas, and analyzed the hot 
spot mutation sites of KIT, PDGFRA and EGFR genes for presence of mutations in glioblastoma. 
Furthermore, we evaluated expression of KIT, SCF and VEGFR2 in paediatric brain tumors and in 
tumour endothelial cells, and studied the intratumoral heterogeneity of EGFR and KIT amplifications 
in primary glioblastomas and astrocytomas. 
 
Mutations turned out to be infrequent in these genes suggesting that neither primary nor secondary 
glioblastomas are usually driven by KIT or PDGFRA mutations, or by EGFR kinase domain 
mutations. No mutations were detected with denaturing high-performance liquid chromatography 
(DHLPC) in KIT exons 9, 11, 13 or 17, PDGFRA exons 12 or 18, or EGFR kinase domain exons 18, 
19 or 21 in a series of 57 glioblastomas. Similarly, no mutations were found in exons coding for the 
extracellular domain II EGFR, and only one mutation was found in an exon coding EGFR domain IV 
among 57 glioblastomas (I).  
 
Unlike gene mutations, amplifications of KIT, VEGFR2, PDGFRA and EGFR turned out to be 
frequent in glioblastoma. KIT was amplified in 47% and VEGFR2 in 39% out of the 43 primary 
glioblastomas investigated, and PDGFRA in 29% (II). As many as 35 (81%) out of the 43 
glioblastomas had either KIT or EGFR amplification. Presence of KIT, PDGFRA and VEGFR2 
amplifications were strongly associated (p < 0.0001 for each pair wise comparison) suggesting co-
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amplification, whereas no significant associations were found between amplifications of these genes 
and EGFR amplification. All four secondary glioblastomas investigated had KIT amplification, 
whereas none harboured EGFR amplification (II). 
 
We investigated presence of gene amplifications also in other types of gliomas, namely in 
astrocytomas (n = 55), anaplastic astrocytomas (n = 39), oligodendrogliomas (n = 37) and 
oligoastrocytomas (n = 27) either in tumour samples collected at the time of the diagnosis or in 
samples collected at the time of tumour recurrence (III). In tumour tissue samples collected at the 
time of the diagnosis KIT and PDGFRA amplifications turned out to be more frequent in anaplastic 
astrocytomas than in astrocytomas, oligodendrogliomas and oligoastrocytomas [28% versus 5% (p = 
0.012) and 33% versus 2% (p = 0.0008), respectively]. VEGFR2 amplifications occurred in 6% to 
17% of the gliomas sampled at the time of the diagnosis, and EGFR amplifications in 0% to 12%. 
Amplified KIT was more frequently present in recurrent gliomas than in newly diagnosed gliomas (19 
out 71 vs. 8 out of 81, respectively; p = 0.0066). KIT amplification was associated with KIT protein 
expression and with presence of PDGFRA and EGFR amplifications both at the time of the first 
diagnosis of glioma and at the time of tumour recurrence, and with VEGFR2 amplification at the time 
of tumour recurrence. Eighty-three samples taken at the first diagnosis of glioma and 74 samples 
collected at the time of tumour recurrence were available for assessment of coamplification of KIT, 
PDGFRA and VEGFR2. Amplification of at least two of the three genes was present more often in 
recurrent gliomas (ten out of 74, 14%) as compared to gliomas studied at the time of the diagnosis 
(three of 83, 4%; p = 0.025). The amplicon contained amplified KIT in all 13 cases (III). 
 
None of the 9 paediatric pilocytic astrocytomas studied with in situ hybridization harboured 
amplification of KIT (IV). In contrast, KIT expression was common in tumour endothelial cells in 
pilocytic astrocytomas, and endothelial cell KIT was frequently activated (phosphorylated). Tumour 
endothelial cell KIT expression was associated with a young age at the time of the diagnosis. 
Ependymomas also frequently expressed KIT in endothelial cells, and its expression tended to be 
associated with a young age at the time of the diagnosis.  
 
Finally, we investigated heterogeneity of KIT and EGFR amplification and their protein products in 
gliomas by studying several tissue blocks from each tumour using FISH and immunohistochemistry, 
respectively (V). EGFR amplification was found in ten (67%) out of the 15 glioblastomas studied 
when CISH analysis was carried out from only one tissue block, and in 11 (73%) cases when all 
available tissue blocks were analyzed. This finding suggests that EGFR amplification is not markedly 
heterogeneous in glioblastoma. In contrast, KIT was amplified in six (40%) out of the 15 index 
glioblastoma tissue blocks, but in 10 (67%) glioblastomas when all tissue blocks were analyzed. 
EGFR, EGFRvIII, KIT and phospho-KIT expression was heterogeneous in immunohistochemical 
staining of the tumors, and occurred at least in one part of tumour in 93%, 33%, 93% and 100% of 
glioblastomas, respectively. None of the seven astrocytomas contained amplified EGFR and only one 
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harboured amplified KIT even when all blocks were examined. These findings suggest that that 
glioblastomas show marked heterogeneity in KIT amplifications and KIT and phospho-KIT 
expression, and that heterogeneity is less for EGFR amplifications and for EGFR and EGFRvIII 
expression. The proportion of glioblastomas with EGFR or KIT amplification may thus be larger than 
reported in the literature when tumour heterogeneity is accounted for.  
 
INTRODUCTION 
 
Tumors of the CNS range from benign neoplasms, such as meningioma, to almost invariably lethal 
cancer, glioblastoma multiforme. Approximately 900 CNS neoplasms are diagnosed in Finland 
annually, and the annual incidence rate of CNS tumors has slowly increased 
(http://www.cancerregistry.fi/). In the Nordic countries, the annual incidence rate of gliomas is 
approximately 10 cases per 100,000 in the age-group of over 40 years (Deltour et al. 2009). 
Malignant gliomas account for approximately 70% of new cases of malignant primary brain tumors 
(Wen and Kesari 2008), and the CNS tumors are the most common solid tumors diagnosed in 
children.  
 
The CNS consists mainly of neurons and glial cells. Neurons conduct electrical signals within the 
neural system, and glial cells, such as astrocytes, provide nutrition, insulation and structural support to 
neurons and their axons to facilitate signal conduction (DeAngelis 2001, Kleihues et al. 2002). 
Gliomas are often classified into four malignancy grades depending on histological findings that 
include cell mitotic activity, presence of tumour necrosis accompanied by areas of palisading cells, 
cell atypia and endothelial proliferation. High mitotic activity, presence of tumour necrosis, marked 
cell atypia and angiogenesis are characteristic features of the most malignant (grade IV) glioma, 
glioblastoma, whereas pilocytic astrocytomas (grade I), astrocytomas (grade II) and anaplastic 
astrocytomas (grade III) do not have all of these features. Most glioblastomas are considered to arise 
de novo without presence of a pre-existing lesion (primary glioblastomas), but they can arise also 
from pre-existing lower grade astrocytoma (secondary glioblastomas).  
 
The median age of patients at
 
the time of the diagnosis glioblastoma is approximately 60 years, and 
45 years at the time when secondary glioblastoma is diagnosed (Fisher et al. 2007; Wen and Kesari 
2008). Patients diagnosed with glioblastoma have a median survival time barely exceeding one year 
following the diagnosis (Kleihues et al. 2002, Ohgaki and Kleihues 2005a), and at present no curative 
treatment is available. In contrast, pilocytic astrocytomas that occur predominantly in children are 
tumors of low malignancy potential can usually be removed completely by surgery and are associated 
with approximately 95% 5-year survival (Fisher et al. 2008). 
The factors that cause genesis of gliomas are incompletely understood. The only established risk 
factor is ionizing radiation (Fisher et al. 2007). Suggested risk factors for glioma include exposure to 
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electromagnetic fields, use of cellular telephones, some food ingredients, immunological factors, viral 
infections and occupational risk
 
factors, but none is currently supported by firm evidence. A small 
proportion (approximately 5%) of patients diagnosed with malignant glioma has a family
 
history of 
gliomas, but most of the glioma patients have no known genetic cause. Gliomas may rarely be 
associated with a genetic syndrome, such as neurofibromatosis type
 
1 or type 2, Turcot's
 
syndrome 
(intestinal polyposis and a brain tumour) or the Li–Fraumeni syndrome (a germ-line TP53 mutation) 
(Farrell et al. 2007). 
 
 
Cancers often harbour many genetic aberrations that eventually lead to tumour invasiveness, 
unlimited growth and metastasis (Hanahan and Weinberg 2000). In gliomas, several genetic and 
epigenetic errors leading to tumour development have been characterized. The involved molecular 
networks include receptor tyrosine kinase (RTK) signalling through the Ras–MAPK and PI3K–AKT–
mTOR pathways, and Wnt and sonic hedgehog (SHH) signalling, along with the cell cycle-regulating 
RB and p53 pathways (reviewed in Huse and Holand, 2010). Recently, mutations in isocitrate 
dehydrogenase I (IDH1) were found to occur in the majority of grade II and grade III gliomas and 
secondary glioblastomas (Dang et al. 2009, Smeitink 2010).  
 
Gene amplifications are frequent in cancer. Amplifications and activating mutations of the genes 
encoding RTKs are of particular interest, since these can now be selectively targeted by monoclonal 
antibodies and small molecule tyrosine kinase inhibitors. Activated RTKs pass cell survival 
promoting signals to the nucleus, and they may direct cells to invasion and metastasis. Primary 
glioblastomas often harbour amplification of the gene encoding for the epidermal growth factor 
receptor (EGFR; Albertson 2006, Collins 2004), but amplification of this gene likely presents only 
one of the many genetic aberrations involved in glioma progression (Behin et al. 2003, Collins 2004, 
Huse and Holand, 2010).  
 
The aim of the present study was to investigate human gliomas, glioblastomas in particular, for 
genetic aberrations in KIT (encodes the receptor of the stem cell factor, SCF), the gene encoding the 
platelet-derived growth factor receptor-alpha protein (PDGFRA), VEGFR2 (encodes vascular 
endothelial growth factor receptor-2) and EGFR. A common nominator of these four genes is that the 
proteins encoded by them are now important therapeutic targets for small molecule tyrosine kinase 
inhibitors in the treatment of several types of human cancer.  
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REVIEW OF THE LITERATURE 
1. Receptor tyrosine kinases   
Receptor tyrosine kinases (RTKs) are a class of proteins that are important in the development, 
maintenance and function of the normal tissues, but they may also play a key role in the genesis of 
some cancers. RTKs are transmembrane growth factor receptors that mediate signals from the cell 
environment into the cell. They regulate fundamental cellular processes, such as the cell cycle, 
migration, metabolism, survival, proliferation and differentiation. During evolution, the first RTK 
likely arose from a fusion of an epidermal growth factor (EGF)–like domain and a cytoplasmic 
tyrosine kinase, which took place before appearance of animals (King and Carroll 2001, Robinson et 
al. 2000a). RTKs share two major functional domains: an extracellular ligand-binding domain and an 
intracellular domain that has tyrosine kinase function (Grassot et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A schematic illustration of receptor tyrosine kinases of the VEGFR, PDGFR and 
EGFR-families. These families share a common overall structure consisting of an extracellular 
domain, a transmembrane region and an intracellular domain, but the ligand-binding extracellular 
domain, in particular, shows structural differences. 
 
RTKs are activated (phosphorylated) following binding of a specific soluble ligand. Phosphorylation 
of tyrosine residues increases kinase enzymatic activity and activates downstream signalling 
pathways (Grassot et al. 2006, Hubbard and Till 2000, Kostich et al. 2002, Robinson et al. 2000). 
Since RTKs are involved in the regulation of the cell, an imbalance in the RTK signalling 
homeostasis may give rise to neoplastic transformation, and dysregulation of RTK signalling occurs 
in various types of human cancer. Several molecular mechanisms may influence this homeostasis. 
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These mechanisms include an increased dose of RTK-specific ligands; an increased number of RTKs 
on the cell membrane; gene amplification, mutation or aberrant regulation of the gene that encodes 
the RTK; abnormal post-translational regulation of messenger-RNAs transcribed to an RTK; 
defective down regulation of RTKs; and abnormal interaction between RTKs and the proteins that 
bind to them including proteinases that cleave of the extracellular portion of the RTK; and 
intracellular phosphatase activity.  
1.1 RTK signalling pathways 
Intracellular cell signalling is mediated by various proteins, micro-RNA and short interfering RNA 
(siRNA) that interact with each other and the DNA within a cell (Feero WG et al. 2010). RTK signal 
is conducted downstream via a cascade of proteins, and eventually the signal is delivered into the 
nucleus where it induces transcription of the target genes. Ligand binding to the cognate RTK causes 
receptor dimerization, autophosphorylation of the adjacent intracellular kinase domains, and 
subsequently activation of one or more signalling pathways, such as the RAS-RAF-MEK-ERK, 
PI3K-AKT, PLCγ-PKC, SRC/JNK or JAK/STAT pathways (Blume-Jensen et al. 1998, Jiang & Liu 
2008, Reber et al. 2006, Roberts & Der 2007, Roskoski 2005a, Wong et al. 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic presentation of basic signalling pathways downstream of an RTK. Upon 
ligand binding and dimerization of the RTK, PI3K/AKT, RAS/RAF/ERK, SRC/JNK, JAK/STAT 
and/or PLCγ/PKC signalling pathways are activated resulting eventually in alteration of gene 
expression and cell function. 
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1.2 Epidermal Growth Factor Receptor–family (RTK Subclass I) 
The epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER-1) is the cell-surface 
receptor for the members of the EGF-family of extracellular protein ligands. The gene encoding this 
protein is located at the chromosomal locus 7p12. EGFR is a member of the ErbB family of receptors 
(www.genome.ad.jp) (Grassot et al. 2006). It resides on the plasma membrane and is activated 
following binding of one of its 11 known ligands, which can be classified into three groups (a) 
ligands that specifically bind to EGFR (EGF, transforming growth factor-a, amphiregulin and 
epigen); (b) those that bind to EGFR and ERBB4 (betacellulin, heparin-binding EGF and epiregulin); 
and (c) neuregulin (NRG) that binds to ERBB3 and ERBB4. NRG1 and NRG2 bind to both ERBB3 
and ERBB4, whereas NRG3 and NRG4 only to ERBB4 (Mitsudomi and Yatabe 2010). In the 
absence of a bound ligand EGFR is a monomer, but ligand binding leads to formation of a receptor 
homodimer. EGFR may dimerize with another member of the ErbB receptor family, such as 
ErbB2/HER2/neu, to create a heterodimer. Ligand-induced EGFR dimerization leads to 
autophosphorylation of several tyrosine residues in the cytoplasm domain of each receptor monomer. 
The best characterized downstream signalling pathways include the RAS-RAF-MEK-ERK, PI3K-
AKT and PLCγ-PKC pathways, which upon activation stimulate cell proliferation, motility and 
survival (Boonstra et al. 1995, Citri & Yarden 2006, Jiang & Liu. 2008, Roberts & Der 2007, Wong 
et al. 2007, Zandi et al. 2007).  
 
Elevated tumour EGFR content is associated with unfavourable survival in several human types of 
human cancer, such as carcinomas of the head and neck, bladder, ovary, uterine cervix and 
oesophagus (Nicholson et al. 2001). Amplification of EGFR, often resulting in increased tumour 
EGFR levels, has been detected in several types of human cancer, such as breast carcinoma, non-
small-cell lung cancer (NSCLC), oesophageal squamous cell carcinoma and in primary glioblastoma 
(Bhargava et al. 2005, Hanawa et al. 2006, Suzuki et al. 2005, Wong et al. 1992). In primary 
glioblastoma, EGFR amplification is present in approximately 30 to 50 percent of the tumors 
(Ekstrand et al. 1991, Frederick et al. 2000, Hui et al. 2001). In the absence of gene amplification 
EGFR overexpression may result from a variety of molecular mechanisms that include increased 
activity of the EGFR promoter or dysregulation at the translational or the post-translational level.  
 
Mutations of EGFR are frequent in human cancers. These can be divided into three main groups 
based on location of the mutation: mutations in the part of the gene that encodes for the RTK 
extracellular domain, those found in the intracellular tyrosine kinase domain, and mutations found in 
the gene sequences that encode the rest of the protein (Zandi et al. 2007). EGFR kinase domain 
mutations are relatively rare; small deletions and point mutations have been detected in NSCLC 
(Huang et al. 2004, Mitsudomi et al. 2005, Paez et al. 2004). In contrast, deletions in the extracellular 
domain involving exons 2 to 7 of EGFR are frequent in glioblastoma, but can be found also in other 
types of cancer, such as prostate cancer, breast cancer, NSCLC, ovarian cancer, and head and neck 
cancer (Fenstermaker & Ciesielski 2000, Frederick et al. 2000, Moscatello et al. 1995, Olapade-
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Olaopa et al. 2000, Okamoto et al. 2003, Sok et al. 2006, Wong et al. 1992). Such a partially deleted 
gene gives rise to truncated, constitutively activated receptors that do not bind ligands and are thus 
not under normal regulation (Zandi et al. 2007).  
 
In glioblastoma, expression of the truncated form of EGFR (EGFRvIII) occurs in approximately 20% 
to 30% of the cases (Gan et al. 2009). EGFRvIII activates not only the same downstream effectors 
pathways as EGFR, but also the c-Jun N-terminal kinase (JNK) via PI3K (Antonyak et al. 1998, Chu 
et al. 1997, Pedersen et al. 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. EGFR: A schematic presentation indicating the exons that code for the extracellular 
domains II and IV, and the tyrosine kinase domain. 
1.3 Platelet Derived Growth Factor Receptor Alpha-family (RTK subclass III)  
Type III receptor protein-tyrosine kinases include the stem cell factor (SCF) receptor (SCFR/KIT), 
the platelet-derived growth factor (PDGF) receptor (alpha and beta), the macrophage colony-
stimulating-factor receptor-1 (CSF1R) and the fms-related tyrosine kinase-3 (FLT3). These receptor 
protein tyrosine kinases all share similar features: an extracellular immunoglobulin-like ligand-
binding domain, a single transmembrane segment and a spilt cytoplasmic kinase domain. The class III 
receptors are characterized by presence of five immunoglobulin-like domains in their extracellular 
portion. KIT and PDGFRA genes are located adjacent at the chromosomal locus 4q12 next to the 
vascular endothelial growth factor receptor-2 (VEGFR2) gene, which belongs to the RTK subclass V 
(Grassot et al. 2006).  
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Figure 4. PDGFRA and KIT RTKs: Exons coding extracellular, transmembrane and intracellular 
tyrosine kinase domains in PDGFRA and KIT receptors. 
1.3.1 Stem Cell Growth Factor Receptor (KIT) 
SCF is the ligand of the KIT receptor tyrosine kinase. KIT binds the SCF with the first three of the 
five immunoglobulin-like loops in the extracellular domain of the receptor. Physiologically SFC may 
exist as a membrane-bound form or as a soluble form. Interaction of the SCF with KIT rapidly 
induces KIT dimerization and increases its autophosphorylation activity. SCF and KIT are critical for 
survival and development of stem cells involved in haematopoiesis, skin pigmentation and 
reproduction, as well as in mast cell development. KIT is also expressed in epithelial cells of the 
breast and in basal cells of the skin. SCF and KIT play a role in the development of the interstitial 
cells of Cajal (ICC) in the intestine, and in the learning functions in the hippocampus region of the 
brain. 
 
Upon KIT dimerization, downstream of KIT multiple signal transduction components are activated. 
These components include PI3K, the SRC family members, the JAK/STAT pathway and the RAS-
RAF-MAP kinase cascade (Grassot et al. 2006, Linnekin. 1999, Reber et al. 2006, Roskoski. 2005b, 
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Tsuura et al. 1994). In addition, the KIT receptor promotes cell survival via activation of PI3K/AKT-
mediated phosphorylation of BAD that regulates cell apoptosis (Blume-Jensen et al. 1998).  
 
Deficiency in the KIT function impairs erythropoiesis, pigmentation of the skin, fertility and 
gastrointestinal peristalsis. KIT may be activated through a gain-of function mutation that may result 
in a malignant phenotype in cells dependent on KIT function. Abundant KIT expression has been 
reported to occur in some sarcomas (notably in GIST), small cell carcinoma of the lung, adenoid 
cystic carcinoma of the head and neck, renal chromophobe carcinoma, as well as in some thymic, 
ovarian and breast carcinomas and in glioblastoma (Miettinen &Lasota 2005, Sihto H et al. 2007). 
 
KIT is often mutated and constitutively activated in gastrointestinal stromal tumors (GISTs), systemic 
mastocytosis and mast cell leukemia. KIT amplifications are rare in GISTs, but high levels of KIT 
protein are detected in most (95%) of these tumors. Approximately 80% of GISTs have activating 
KIT mutations that are most commonly located in exons 11 and 9 of the gene. Rarely, KIT exon 13 
and 17 mutations are found in GISTs that have not been exposed to imatinib or other tyrosine kinase 
inhibitors (Hornick & Fletcher 2002, Joensuu et al. 2002, Miettinen & Lasota 2005, Sihto et al. 2005, 
Tabone et al. 2005). Most GISTs are probably either KIT or PDGFRA driven tumors. They probably 
originate from a precursor cell of the ICC based on their phenotypic resemblance with this cell 
phenotype (Corless et al. 2004, Hirota et al. 1998, Kindblom et al. 1998, Sarlomo-Rikala et al. 1998). 
The ICCs are located in the gastrointestinal tract, where they regulate peristalsis and mediate 
autonomic nervous system functions (Hirota et al. 1998, Huizinga et al. 1995, Kindblom et al. 1998, 
Maeda et al. 1992, Miettinen & Lasota 2005, Sarlomo-Rikala et al. 1998, Torihashi et al. 1999). 
 
GIST may rarely arise also in children and young adults. In paediatric GISTs KIT and PDGFRA 
mutations are far less common than in adult tumors, and imatinib is generally less effective than in the 
treatment of adult GISTs. Despite lack of KIT mutations, these tumors have often activated KIT, but 
their molecular pathogenesis is likely heterogeneous (Janeway et al. 2007).  
 
Epidermal melanocytes and mast cells express KIT constitutionally, and KIT is likely important in 
their development and function. Primary malignant melanomas and their metastasis show variable 
KIT expression. Imatinib has recently been found to be effective in a proportion of patients who have 
either mucosal melanoma, acral melanoma or melanoma arising in sun exposed skin. In one study, 
KIT mutations were found in 38% of mucosal and in 6% of acral melanomas, and their presence may 
likely be used as a guide for treatment selection (Handolias et al. 2010). KIT activating mutations 
have been detected in human mast cell neoplasms, most of them in exon 17. Of germ cell tumors KIT 
may be expressed in seminomas, and a majority of classic testicular seminomas express KIT. One 
third of seminomas and their extra testicular analogs harbour KIT mutations. The reported point 
mutations are located in exon 17. In addition, a few point mutations and deletions of exon 11 have 
been reported in testicular tumors (Hawkins E et al. 1997, Kemmer K et al. 2004, Looijenga LH et al. 
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2003, Przygodzki et al. 2002, Rapley et al. 2004, Sakuma et al. 2003, Sakuma et al. 2004, Tian et al. 
1999). A gain in the copy number of KIT and KIT overexpression may be associated with progression 
of carcinoma in situ to an invasive testicular germ cell tumour (McIntyre et al. 2005).  
 
KIT is expressed in a subset of hematopoietic stem cells, and it likely has an important role in 
erythropoiesis. KIT-deficient mice develop hypoplastic bone marrow and macrocytic anaemia 
(Waskow et al. 2004). Approximately 70% of acute myeloid leukemias (AMLs) express KIT (Bene et 
al. 1998, Escribano et al. 1998, Kanakura et al. 1993, Schwartz et al. 1999, Valverde et al. 1996). 
Some adult sarcomas, including angiosarcomas, are also occasionally KIT-positive in 
immunostaining, although mutations in KIT exons 11 or 17 are lacking (Miettinen et al. 2000; 
Hornick & Fletcher 2002). Hemangioendotheliomas and hemangiomas are usually KIT-negative, but 
KIT may be expressed in juvenile hemangiomas of the immature phenotype (Miettinen et al. 2000, 
Miettinen & Lasota 2005).  
 
In the normal kidney, KIT is expressed in distal nephrons, and it is expressed in normal fetal and adult 
renal tubules (Kato et al. 2005, Miliaras et al. 2004). KIT is expressed in some malignant renal 
tissues, such as renal chromophobe cell carcinomas and very frequently in oncocytomas, but 
mutations of KIT or PDGFRA have not been found (Kato et al. 2005, Miliaras et al. 2004). KIT may 
be expressed in paediatric renal tumors, but KIT mutations or amplifications are not present. KIT 
expression may be associated with unfavourable outcome in a subset of Wilm’s tumors and clear cell 
sarcomas of the kidney, and it is expressed in a proportion of paediatric synovial sarcomas, 
osteosarcomas and Ewing sarcomas (Jones et al. 2007, Smithey et al. 2002). 
1.3.2 Platelet Derived Growth Factor Alpha (PDGFRA) 
PDGFRs and their ligands, platelet derived growth factors (PDGFs), are important in mesenchymal 
cell migration and proliferation. During embryogenesis the PDGF/PDGFR system is essential e.g. in 
the development of the cardiovascular system, the brain and the lungs. In adults, PDGF/PDGFR 
signalling is involved in angiogenesis, wound healing and inflammation.   
 
The PDGF family consists of PDGF-A, -B, -C and -D ligands. The PDGFs bind to the protein 
tyrosine kinase receptors PDGFR-alpha and -beta (PDGFRA and PDGFRB, respectively). These two 
receptors dimerize upon binding of the PDGF dimer, leading to three possible receptor combinations 
(AA, BB or AB) (Heidaran et al. 1990, Matsui et al. 1989).  
 
Abnormalities in PDGF/PDGFR signalling contribute to several human diseases and malignancies 
(Jones & Cross 2004). Constitutive activation of PDGFRA is present in some myeloid malignancies 
as a consequence of formation of a fusion gene. Activating mutations of PDGFRA are present in a 
subset of GISTs.  
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The structure of PDGFRA is very similar to KIT: five immunoglobulin–like extracellular domains, a 
transmembrane domain, an intracellular juxtamembrane domain, a split tyrosine kinase domain with a 
kinase insert and a C-terminal tail. Activating mutations of PDGFRA occur most commonly in the 
activation loop (exon 18) and in the juxtamembrane region coding exon 12 (Blume-Jensen & Hunter 
2001, Heinrich et al. 2003, Jones & Cross 2004, Kawagishi et al. 1995, Sihto et al. 2005).  
 
In low grade astrocytomas, one of the earliest molecular alterations includes overexpression of 
PDGFA/PDGFRA, which creates an autocrine growth-factor stimulation loop. Amplification of 
PDGFRA is a common molecular genetic aberration associated with diffusely infiltrating astrocytic 
gliomas and secondary glioblastomas (Behin et al. 2003, Reifenberger & Collins. 2004). 
1.4 The Vascular Endothelial Growth Factor Receptor-family (RTK subclass V) 
Vascular endothelial growth factors (VEGFs) mediate angiogenic signals to the vascular endothelium. 
They are classified as class V receptor tyrosine kinases, and show structural similarities to the 
subclass III RTKs except that they have seven immunoglobulin-like loops in the extracellular domain 
(Figure 1). Three receptors have been identified that specifically bind VEGF. These receptors have 
been named VEGFR1, VEGFR2 and VEGFR3. In the adult, VEGFR1 and VEGFR2 are expressed 
mainly in the blood vascular endothelium, whereas expression of VEGFR3 is restricted largely to the 
lymphatic endothelial cells (Grassot et al. 2006, Veikkola et al. 2000). VEGFR2 is a high-affinity 
receptor for the potent angiogenic ligands VEGF-A and VEGF-B, and the processed forms of VEGF-
C and VEGF-D.  
 
VEGFs and their endothelial receptors are key regulators of angiogenesis, vasculogenesis and 
lymphangiogenesis. VEGFR-1 may act as a stimulator of pathological angiogenesis when activated 
by its ligands VEGF-B and PlGF (placental growth factor). PlGF recruits angiogenic macrophages to 
tumors. VEGF-C and VEGF-D induce lymphangiogenesis via VEGFR-3, but VEGFR-3 is important 
also for angiogenesis acting together with VEGF/VEGFR-2 and Dll4 (Delta-like protein 4)/Notch 
signalling to control angiogenic sprouting (Lohela et al. 2009). Angiopoietin-2 and the Tie2-receptor 
(tyrosine kinase with immunoglobulin-like and EGF-like domains-1) are also involved in tumour 
angiogenesis, where Tie2 utilizes a unique signalling mechanism at the endothelial cell-cell junctions 
(Saharinen et al. 2010).  
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2. Cells and tumors of the central nervous system 
Tumors of the nervous system account for less than 2% of all human malignancies. Yet, 
approximately 175,000 new cases are diagnosed worldwide annually, probably without a large 
variance in the incidence between geographic regions or populations. Gliomas are the most common 
brain tumors, with an annual incidence of 5 to 10 cases per 100,000 persons. Gliomas are believed to 
arise from the glial cells of the CNS that provide nutrition, insulation and structural support for 
neurons and neuronal axons, and thus facilitate signal conduction (DeAngelis. 2001, Kleihues et al. 
2002). 
 
Glial cells or neuroglia consists of ependymal cells, oligodendrocytes and astrocytes; the latter are 
also known collectively as astroglia. Radial glial cells, Schwann cells and satellite cells have various 
functions ranging from insulation and to microenvironmental control within the brain. Microglia are 
glial cells that act in active immune defence of the brain. Ependymal cells form the lining of the 
ventricular system, and ependymal cells are believed to contribute to the cerebrospinal fluid flow and 
homeostasis (Meiniel 2007). Oligodendrocytes are myelin-forming glial cells. The neurons are 
dependent on the myelin sheath provided by the oligodendroglial cells, since myelin provides 
insulation and allows fast neurotransmission. The Schwann cells are responsible for the myelin 
production in the peripheral nervous system.  
 
The most abundant type of glial cells are astrocytes, star-shaped cells that give support to the 
endothelial cells at the blood-brain-barrier (BBB), provide nutrition to the nervous tissue and 
participate in repair of the brain tissue. Astrocytoma is a tumour likely derived from these cells, and 
the tumour cells in astrocytoma resemble morphologically normal astrocytes. Similarly, 
oligodendrogliomas are defined by the presence a major oligodendrocyte population in the tumour. 
Mixed forms of these tumour types exist, and the most malignant glial tumors rarely consist of one 
homogeneous cell population. Based on histological classification, astrocytomas, oligodendrogliomas 
and ependymomas belong to tumors of neuroepithelial origin (Bene et al. 1998, Cavaliere et al. 2005, 
Collins. 2004, DeAngelis 2001, Kleihues et al. 2002, Louis et al. 2007).  
 
Tumour stem cells have been implicated in formation of glial tumors. Oligodendrocytes and 
astrocytes may have a common progenitor cell in the subventricular zone (Carmen et al. 2007), and 
neuroglial precursors are thought to emigrate from this spatially restricted germinal zone to colonize 
the hemispheres (Levison et al. 1993). In case of ependymal tumors, the radial glial cells are thought 
to be candidate stem cells that give rise to this tumour type (Taylor et al. 2005, Poppleton & 
Gilbertson 2007, Vescovi et al. 2006). Neural stem cells have been identified in the mature CNS, and 
new neurons and glial cells are produced throughout life from these neural stem cell niches (Galli et 
al. 2004, Galli et al. 2008).  
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Glial tumors are often composed of heterogeneous cell populations containing also small 
subpopulations of highly proliferative immature precursor cells that may or may not be neural 
CD133-positive stem cells, which may contribute to tumour initiation (Chen et al. 2010). The 
etiology and causes of gliomas are still unclear. Variable environmental factors have been suggested 
as risk factors for glioma, but the data are mostly contradictory or inconclusive. Few studies suggest 
an increase in the incidence of malignant gliomas over time, but these findings may be confounded by 
prolonged life expectancy and increased use of brain imaging. High-dose ionizing radiation, some 
genetic syndromes (such as neurofibromatosis, tuberous sclerosis and Li-Fraumeni syndrome) and old 
age are the only generally accepted risk factor for glial neoplasms, and some hereditary syndromes for 
menigeomas (Bondy et al. 2008). Gliomas hardly ever spread outside of the CNS or give rise to 
metastases in other internal organs. However, gliomas often have a diffuse growth pattern within the 
tissue, and, hence, their surgical removal usually remains partial (Cavaliere et al. 2007, DeAngelis 
2001) 
Table 1A. Histological classification of selected CNS tumors: location, age at clinical 
manifestation and 5-year survival.*  
Tumors of neuroepithelial tissue Typical location 
Age at manifestation 
 (% of cases) 
5-year 
survival 
(%) 
0-20 
years 
20-45 
years 
>45 
years 
Astrocytic tumors 
Pilocytic astrocytoma (grade 1) 
 
 
Cerebellum, optic 
nerve 
 
74 20 6 >85 
 
Astrocytoma (grade 2) 
 
 
Anaplastic astrocytoma (grade 3) 
 
Cerebral hemispheres 
 
Cerebral hemispheres 
10 
 
 
11 
61 
 
 
34 
29 
 
 
55 
>50 
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Glioblastoma multiforme (grade 4) 
 
Cerebral hemispheres 3 25 72 <3 
Oligodendroglial tumors      
 
Oligodendroglioma/  
Anaplastic oligodendroglioma 
Cerebral hemispheres 8 46 46 >50 
 
Ependymal tumors 
     
Ependymoma (grade 2) 
Ventricles,  
spinal cord 
37 38 25 <30 
Medulloblastoma (grade 4) Cerebellum 74 23 3 >50 
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Table 1B. Other histological types of CNS tumors.* 
 
Astrocytic tumors Pineal parenchymal tumors 
 Pineocytoma 
Pleomorphic xanthoastrocytoma Pineoblastoma 
Subependymal giant-cell astrocytoma Embryonal tumors 
Oligodendroglial tumors Primitive neuroectodermal tumour 
Mixed gliomas Meningeal tumors 
Oligoastrocytoma Meningioma 
Anaplastic oligoastrocytoma Hemangiopericytoma 
Ependymal tumors Melanocytic tumour 
Anaplastic ependymoma Hemangioblastoma 
Myxopapillary ependymoma Primary central nervous system lymphomas 
Subependymoma Germ-cell tumors 
Choroid-plexus tumors Germinoma 
Choroid-plexus papilloma Embryonal carcinoma 
Choroid-plexus carcinoma Yolk-sac tumour (endodermal-sinus tumour) 
Neuronal and mixed neuronal–glial tumors Choriocarcinoma 
Gangliocytoma Teratoma 
Dysembryoplastic neuroepithelial tumour Mixed-germ-cell tumors 
Ganglioglioma Tumors of the sellar region 
Anaplastic ganglioglioma Pituitary adenoma 
Central neurocytoma Pituitary carcinoma 
Metastatic tumors Craniopharyngioma 
*Modified from (DeAngelis. 2001, Kleihues et al. 2002 Ohgaki & Kleihues 2005a and b, Surawicz et 
al. 1998). 
2.1 Astrocytic tumors  
Astrocytomas are usually found in the cerebral hemispheres. Adult gliomas may show histological 
variations that may make their classification demanding. The WHO classification grading is based on 
the number of mitoses, presence of nuclear atypia, microvascular proliferation and tumour necrosis 
(DeAngelis 2001, Kleihues et al. 2002). Diffuse low grade astrocytomas (WHO grade 2) are well 
differentiated tumors with a low density of tumour cells that infiltrate diffusely into the brain 
parenchyma. The mitotic activity is low, and necrosis and microvascular proliferation are absent. 
Diffuse low-grade astrocytomas tend to progress into anaplastic astrocytomas (WHO grade 3) and 
eventually to glioblastoma (WHO grade 4) (Behin et al. 2003). The grade 4 gliomas are also called 
“glioblastoma multiforme” reflecting the heterogeneity of these tumors. Glioblastomas may present 
with varying cell morphology within the tumour, where high grade malignant areas with atypical 
tumour cells may be adjacent to morphologically less anaplastic tumour cells or endothelial 
proliferations.  
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Primary glioblastomas are usually diagnosed among older patients, whereas the lower grade gliomas 
tend to affect younger adults, although the age distribution at presentation is wide. The mean age of 
adult glioma patients is 40 to 45 years at the time of the diagnosis and that of glioblastoma patients 55 
to 60 years (DeAngelis 2001, Kleihues et al. 2000, Ohgaki & Kleihues 2005a). Patients diagnosed 
with anaplastic astrocytoma have a median survival time of approximately 3 years after the diagnosis, 
but the median survival time is only approximately 1 year following the diagnosis of glioblastoma 
(DeAngelis 2001). 
 
The current treatment of malignant gliomas is surgical resection, radiation therapy and in selected 
cases chemotherapy, notably temozolomide in glioblastoma. Unfortunately, none of these treatments 
is curative. Small tyrosine kinase inhibitors such as imatinib, geftinib and erlotinib have limited 
activity in the treatment of gliomas (Behin et al. 2003, DeAngelis. 2001, Dresemann. 2005, Reardon 
et al. 2005, Rich et al. 2004). 
2.1.1 Molecular pathogenesis of glioblastomas and grade 2 and 3 astrocytomas 
EGFR amplifications, mutations and re-arrangements are frequently present in glioblastoma.  
Amplification of EGFR and subsequent over-expression of the EGFR protein are probably the most 
common genetic alterations in primary glioblastoma, and occur at a frequency of about 40% (Gan HK 
et al. 2009). Approximately 70% of the glioblastomas that over-express EGFR have re-arrangement 
of EGFR (Ekstrand et al. 1991). The most common of EGFR mutations is the deletion variant 
EGFRvIII, where 267 amino acid residues have been deleted from the extracellular domain of EGFR 
as a result from deletion of exons 2 to 7 from the gene. This results in inability of the truncated 
protein to bind any known growth factor, but the truncated receptor remains constitutively active and 
signals for a prolonged time as a result from impaired protein endocytosis and degradation due to 
deficient ubiquitination (Huang et al. 1997). Most glioblastomas (50% to 60%) that show 
amplification of EGFR express EGFRvIII (20% to 30% of all unselected glioblastomas). EGFRvIII 
can signal through homodimers or through heterodimers with e.g. EGFR or HER2. Glioma cells have 
been found also to secrete microvesicles expressing EGFRvIII that are released into cellular 
surroundings and the blood of tumour-bearing mice, and can merge with the plasma membranes of 
cancer cells lacking EGFRvIII. These events lead to the transfer of oncogenic activity via the 
microvesicles (Al-Nedawi et al. 2008).  
 
EGFR is located on chromosome 7. Yet, the most frequent genetic alteration in primary glioblastomas 
(occurs up to 80% of cases) is LOH on chromosome 10 (Ohgaki & Kleihues 2009), which finding 
underlines presence of many genetic rearrangements in glioblastoma. Several genetic alterations may 
occur when diffuse astrocytoma is transformed to anaplastic astrocytoma, and eventually to secondary 
glioblastoma. EGFRvIII is less prevalent in secondary glioblastomas compared to primary 
glioblastomas (Gan et al. 2009). At a population level, one of the early genetic rearrangements in 
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secondary glioblastoma includes mutation of TP53, which is found in over 60% of the tumors. TP53 
mutations exist in primary glioblastomas, but not as frequently as in secondary glioblastomas (28% 
vs. 65%) (Ohgaki & Kleihues 2009). Amplification MDM2 is not frequent in glioblastoma (<15%), 
and occurs exclusively in primary glioblastomas that lack TP53 mutation (Ohgaki & Kleihues 2009, 
Rao et al. 2010). In secondary glioblastomas DCC (Deleted in Colorectal Carcinoma) tumour 
suppressor gene expression is frequently lost, and tumors often have amplified PDGFR (Reifenberger 
& Collins 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Genetic pathways to secondary and primary glioblastoma. Glioblastoma may develop 
de novo without a pre-existing lower grade tumour. These tumors are called primary glioblastomas, 
and they frequently contain ERGR amplification and express EGFR. The alternative pathway entails 
gradual glioma development from a pre-existing lower grade lesion. Such glioblastomas are called 
secondary, and are characterized by presence of the PDGFA growth factor and its receptor 
(PDGFRA), and IDH1 and IDH2 mutations. These two pathways are distinct but not mutually 
exclusive (Behin et al. 2003, Ohgaki & Kleihues 2007, Reifenberger & Collins 2004). 
 
2.1.1.1 Isocitrate dehydrogenase-1 mutations 
Isocitrate dehydrogenase-1 (IDH1) mutations were recently discovered as a frequent and early 
alteration in human brain tumors (Dang et al. 2009). Interestingly, these data suggest for the first time 
that the molecular pathway to low grade astrocytomas, oligodendroglial tumors and secondary 
glioblastomas may have a common origin. Primary glioblastomas rarely harbour IDH1 mutations, 
suggesting that primary and secondary glioblastomas originate from a different cell. The histological 
criteria for the differential diagnosis between low-grade astrocytomas, oligodendrogliomas and 
oligoastrocytomas are subjective, and since most of these low-grade gliomas are can now be 
genetically characterized either by the presence of IDH1 mutation and TP53 mutation (secondary 
glioblastomas, low grade astrocytomas) or an IDH1 mutation and 1p/19q loss (oligodendrogliomas 
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and anaplastic oligodendrogliomas).The molecular classification  may augment or even eventually 
replace the histological classification of diffuse gliomas (Ohgaki & Kleihues 2009). 
Isocitrate dehydrogenase-1 (encoded by IDH1 at 2q33) is normally in the cytosol and peroxisomes, 
and catalyzes oxidative carboxylation of isocitrate to α-ketoglutarate, generating NADPH from 
NADP
+ (Smeitink 2010). Forced expression of mutant IDH1 reduces formation of α-ketoglutarate in 
cultured cells and increases HIF1α levels. This may facilitate tumour growth (Zhao et al. 2009). 
IDH1 mutations were first identified by Parsons et al. in glioblastoma multiforme (Parsons et al. 
2008), and they were subsequently found in over 80% of anaplastic astrocytomas, low-grade 
astrocytomas, anaplastic oligodendrogliomas, oligodendrogliomas, oligoastrocytomas, anaplastic 
oligoastrocytomas and secondary glioblastomas (Yan et al. 2008, Blass et al. 2009, Watanabe et al. 
2009). Of note, IDH1 mutations are infrequent (<5%) or absent in primary glioblastomas, pilocytic 
astrocytomas, ependymomas and other CNS tumors. The IDH1 mutation frequency mapping thus 
suggests that low grade astrocytomas, secondary glioblastomas, oligogendrogliomas and 
oligoastrocytomas may share the same cell of origin. Since IDH1 mutations
 
occur predominantly in 
younger patients and are associated with
 
a better prognosis than is the case with tumors that do not
 
carry the IDH1 mutation, D-2-hydroxyglutarate may become a biomarker
 
serving diagnostic, 
prognostic and therapeutic purposes (Smeitink 2010). 
2.1.1.2 Intratumoral heterogeneity of EGFR amplification in glioblastomas 
Glioblastomas frequently display morphological, cytological and genetic heterogeneity (Furnari et al. 
2007, Jung et al. 1999, Kleihues et al. 2002, Maher et al. 2001), and genetic intratumoral 
heterogeneity has long been known to occur in glioblastomas (Harada et al. 1998, Ren et al. 2007). 
EGFR amplification has been found in approximately 40% of glioblastomas when studied usually by 
in situ hybridization techniques and from one tissue block, but the observed frequency varies 
substantially in single studies ranging from 24% to 73% Fischer et al. 2008, Guillaudeau et al. 2009, 
Kramar et al. 2007, Layfield et al. 2006, Lopez-Gines et al. 2005, Miyanaga et al. 2008, Necesalová 
et al. 2007). A Systematic study on intratumoral heterogeneity of EGFR, PDGFRA and MET 
amplification reveal that in gliobalstomas, subpopulations with different RTK amplifications exist but 
cells with different amplifications are actually subclones with common CDKN2A homozygous 
deletions and TP53 mutations, and thus cells with different RTK amplifications do not originate 
independently but are derived from the same precursor (Snuderl et al. 2011). 
2.2 Paediatric CNS tumors 
Tumors of the brain or the spinal cord are the most common solid tumors of the childhood. The most 
common histological tumour type is astrocytoma that accounts for approximately one third of all 
paediatric brain tumors (Larouche et al. 2007, Rickert et al. 1997). Most of the astrocytic tumors are 
low grade (Rickert et al. 1997). Medulloblastomas and ependymomas each comprise approximately 
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10% of the paediatric brain tumors. The most important prognostic factors are tumour histology 
(whether classified malignant or not) and completeness of resection (Larouche et al. 2007).  
2.2.1 Pilocytic astrocytoma 
Pilocytic astrocytomas (WHO grade 1) account for more than 20% of all CNS tumors in children 
aged less than 15, and they mainly occur in children and in young adults (Jones et al. 2006). Pilocytic 
astrocytomas are highly angiogenic showing endothelial-cell proliferation and haemorrhages, but still 
usually slow-growing, and are considered benign tumors (Gesundheit et al. 2003, Reifenberger & 
Collins. 2004). These tumors are typically well-circumscribed and occur in the cerebellum or at the 
optic tract (Reifenberger & Collins. 2004). Histologically, they exhibit a biphasic pattern with bipolar, 
highly fibrillated astrocytes accompanied by Rosenthal fibers adjacent to microcystic regions. The 
astrocytes frequently show granular bodies. Cell atypia, mitoses and necrotic areas that are 
characteristic to high grade gliomas are lacking, reflecting their benign nature (Reifenberger & 
Collins. 2004).   
 
Pilocytic astrocytomas usually do not contain the molecular genetic alterations involved in the 
progression of diffuse astrocytomas, such as TP53 mutations (Haapasalo et al. 1999, James & Collins 
1992, Ohgaki et al. 1993 Ransom et al. 1992 von Deimling et al. 1994). In classic pilocytic 
astrocytomas wild type TP53 most likely drives apoptosis, which is compatible with their generally 
indolent clinical course. Patients diagnosed with pilocytic astrocytoma with classic features have 
usually better survival than patients whose pilocytic astrocytoma has mixed tumour components 
(Haapasalo et al. 1999). Pilocytic astrocytoma can be cured by resection, but they recur if surgical 
extirpation remains partial (Haapasalo et al. 1999). 
2.2.1.1 Genetic aberrations in pilocytic astrocytoma 
Pilocytic astrocytomas have a generally favourable outcome, and the genetic rearrangements that 
promote aggressive tumour growth and behaviour are thus expected to be relatively scarce. There is 
some evidence suggesting that adult and juvenile pilocytic astrocytomas differ genetically. Gains of 
chromosomes 5 and 7, and gain of 9q have been detected more frequently in pilocytic astrocytomas of 
patients older than 15 at the time of the diagnosis (Jones et al. 2006, Sanoudou et al. 2000). 
Intratumoral analysis of pilocytic astrocytomas has revealed chromosomal heterogeneity associated 
with variations in histological morphology, e.g. gains of chromosomal material in 4q and 6q in 
tumour regions consisting of the classic biphasic pattern (Wemmert et al. 2006). Overall, 
chromosomal polyploidy of pilocytic astrocytomas is rare, and usually detected in those tumors that 
have undergone transformation into a more malignant direction (Mathew et al. 1996, Tomlinson et al. 
1994b).  
 
However, pilocytic astrocytomas have some distinctive genetic features compared to diffusely 
growing astrocytic tumors. These features include relatively rare RTK overexpression on tumour cells 
and down regulation of EGFR. Gene expression profiles of pilocytic astrocytomas have revealed few 
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genes that are distinct from higher grade gliomas and also from the normal brain tissue. When 
pilocytic astrocytomas were compared to the normal brain tissue and grade 2 astrocytomas, a strong 
overexpression of TIMP4 (tissue inhibitor of metalloproteinases 4) gene was detected. TIMP4 is able 
to inhibit directly a group of matrix metalloproteinases that act as proteolytic enzymes. Similar 
findings were done with IGFBp2 (insulin-like growth factor binding protein 2) gene and with some 
genes involved in the maintenance of the extracellular environment and lipid metabolism. IGFBp2 is 
produced in various regions in the CNS and is thought to inhibit IGF (insuline-like growth factor)-
stimulated events such as mitogenesis and cell migration. Comparison of gene expression between  
glioblastomas and pilocytic astrocytomas indicated upregulation of a subset of genes involved in 
invasion and angiogenesis in glioblastomas, whereas pilocytic astrocytomas were characterized by the 
expression of genes involved in metabolism, proteolysis, signal transduction and cell adhesion (Colin 
et al. 2006, Rorive et al. 2006). 
2.2.2. Ependymoma 
Ependymomas are tumors of the neuroectodermal origin, and are typically located in the spinal cord 
or adjacent to the ventricles. In addition, ependymomas can sometimes be found in the brain 
parenchyma (Centeno et al. 1986, Oppenheim et al. 1994). Although ependymomas occur in all age 
groups (Reni et al. 2007), the median age at presentation is approximately 4 years. Ependymomas are 
somewhat more common in males than females (McGuire et al. 2009). Surgery is the standard 
treatment for ependymoma. Postoperative radiotherapy is indicated in the treatment of high-grade 
ependymoma and in case where surgical resection is incomplete (Reni et al. 2007).   
 
Prognosis of spinal ependymomas is more favourable than that of infratentorial or supratentorial 
ependymomas. 5-year survival of paediatric ependymomas generally improves with increasing age. In 
the U.S. Surveillance Epidemiology End Results (SEER) database, 45.5% of the patients diagnosed 
with ependymoma survived for 5 years after the diagnosis in the age group of 0-4, whereas the 
survival rate improved up to 77.0% when ependymoma was diagnosed at the age of 16 to 18 
(McGuire et al. 2009) and the oldest age-group (over 45) and infants had the least favourable survival 
rates (Reni et al. 2007).  
 
Ependymomal tumors are classified by the WHO into grades 1 to 3. The WHO grade 1 and 2 
ependymomas have a low mitotic activity and regular nuclear morphology, whereas anaplastic 
ependymomas (the WHO grade 3) are highly cellular, show cell and nuclear pleomorphism and 
endothelial cell proliferation, have frequent mitoses and contain tumour necroses. Perivascular 
rosettes are a histological hallmark of ependymoma (Reni et al. 2007). Anaplastic ependymomas 
exhibit more rapid growth than grade 1 or 2 ependymomas (Kleihues et al. 2002, Schiffer et al. 
1991). 
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Little is known about the risk factors or about the genetic basis of ependymomas. A possible 
relationship between polyomavirus SV40 infection and ependymoma has been suggested, but has not 
been confirmed (Bergsagel et al. 1992, Lednicky et al. 1995). Data about the cytogenetic features of 
ependymoma are also scarce. Frequent mutations or amplifications of receptor tyrosine kinases have 
not been described. TP53 has probably only a minor role in tumour progression (Bijlsma et al. 1995, 
Metzger et al. 1991, Sato et al. 1996). Amplification of MDM2 was detected in 35% of 
ependymomas, and MDM2 overexpression was present in as many as up to 96% of the tumors 
analyzed (Suzuki & Iwaki 2000).  
2.2.3 Medulloblastoma 
Medulloblastomas originate from embryonal or fetal precursor cells, and are typically diagnosed at 
the age of 3 to 6. These tumors are highly malignant, but they respond to radio- and chemotherapy 
(Kleihues et al. 2002). Long-term survival can be achieved in approximately 85% of the standard risk 
patients and 70% of the high risk patients with a combination of chemotherapy and irradiation (Dhall 
2009). The late adverse effects of multimodality treatment (particularly those of radiation therapy) 
may be substantial, and, therefore, novel approaches such as proton therapy are under evaluation with 
promising early results (Yock et al. 2010).  
 
The wingless (WNT) pathway coordinates several developmental processes, and mutations in proteins 
of the WNT pathway occur in approximately 15% of sporadic medulloblastomas (Gilbertson 2004, 
Wechsler-Reya & Scott 2001). Aberrant signalling of the sonic hedgehog pathway is implicated in 
causing medulloblastoma in approximately 20% of children with this disease, and orally active 
inhibitors that bind to the SMO receptor are currently being tested in the treatment of 
medulloblastoma (Gajjar et al. 2010). Approximately 30% of childhood medulloblastomas contain 
amplified N-MYC (Lengauer C et al. 1998). 
3. Gene amplifications in cancer  
Gene amplification is defined as a greater than the normal number of gene copy numbers at a specific 
chromosomal locus. In cancer, presence of gene amplification is one molecular mechanism that may 
enhance tumour growth and progression. The amplicon usually contains at least one gene that is 
strongly expressed abetting amplifications also in adjacent genes that may be irrelevant to tumour 
progression and that may not be expressed (Knuutila 2004). 
 
Recent studies where the entire tumour genome was sequenced typically reveal presence of numerous 
genetic aberrations in a single tumour including gene amplifications and gene deletions (Stephens et 
al. 2009). Amplifications of growth promoting genes are frequent in late stage cancers. Some tumour 
types have characteristic gene amplifications that are associated with overexpression of the gene 
product. For instance, approximately 15 to 20% of breast cancers harbour amplification of HER2 
oncogene, overexpress the protein and are associated with generally unfavourable outcome unless 
treated with anti-HER2 targeted therapy (Ross & Fletcher 1998, Slamon & Press 2009). Another 
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example is amplification of N-MYC (V-myc myelocytomatosis viral oncogene homolog) in 
neuroblastoma. This gene belongs to the MYC family of transcription factors and was one of the first 
tumour amplifications studied in a detail. Amplification of N-MYC has been reported to occur in 
approximately 20% of neuroblastomas, where it is associated with aggressive clinical behaviour of 
the disease (Savelyeva & Schwab 2001).  
 
The size of the amplified genetic material may range from only one gene or few genes to whole 
chromosomal arms, or may span even an entire chromosome. Gene amplification can present as a 
homogeneously staining region (HSR) that consists of DNA sequence repeats within a chromosome, 
or the amplified DNA can exist as extrachromosomal bodies called double minutes (Dmins). The 
double minutes are readily detectable by molecular biological methods (Albertson 2006).  
 
Some chromosomal regions may be prone to undergo amplification. Genomic sequences that have 
received much attention are the chromosomal fragile sites, which are chromosomal regions that 
replicate late during the S-phase and are prone to breakage under conditions of replication stress. 
Gene amplifications are abundant in tumour cells with inactive TP53. Factors such as radiation, 
hypoxia and chemotherapy agents may also induce chromosomal breakage. There is a heterogeneous 
group of approximately 100 fragile sites in the human genome, identified by treating cells with agents 
that interfere with DNA replication (Glover et al. 2005, Wahl et al. 1984). Fragile sites can be divided 
into common and rare sites based on their prevalence in a population. Common fragile sites are 
present in all individuals, and they coincidence with the amplification boundaries found in cell lines. 
The amplification hot spots occur at the same loci as many of the known amplification-activated 
oncogenes (Myllykangas & Knuutila 2006)  
 
Amplification may be initiated by a DNA double strand break that is present at a frailty check point of 
the cell cycle. A double-strand DNA break in a replicating cell can be generated by collapse of the 
replication fork, which is unable to progress as a result of a rearrangement in the DNA. In addition to 
specific breakage-promoting sequences at the fragile sites, errors in DNA replication and telomerase 
dysfunction may also be involved in the genesis of DNA amplifications (Albertson. 2006, Chernova 
et al. 1998, Coquelle et al. 1997, Paulson et al. 1998, Pipiras et al. 1998). Amplification resulting 
from telomere dysfunction is thought to occur through breakage–fusion–bridge (BFB) events as 
originally proposed based on observations made in studies on maize (McClintock 1942, Murnane & 
Sabatier 2004).  
 
Dmins are thought loop out from the chromosomes following breakage of replication bubbles. Dmins 
containing tandem repeats may also be formed in HSR breakdown, where DNA fragments are clipped 
out and fused into circular elements. Dmins may be integrated back into chromosomes and constitute 
a HSR. The HSR gene amplifications are not necessarily restricted to these chromosomal loci of 
amplified genes, but they can be present also elsewhere in the genome as distributed insertions 
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(Albertson 2006). According to the BFB model suggested by Barbara McClintock (1942), the 
initiating event in formation of a HSR is uncapping of a DNA sequence by a double strand break or 
telomere erosion, and post-replication fusion of the two sister chromosomes probably by DNA repair 
proteins. The resulting dicentric fused chromosome forms an anaphase bridge when it is drawn by the 
two centromeres of the fusion chromosome to the opposite poles of the mitotic spindle. This stress 
can cause a secondary breakage of the chromatin and uneven segregation of the DNA material into 
the daughter cells, and a repeat of the BFB in every cell division eventually leads to gene 
amplification (Myllykangas & Knuutila 2006).  
 
3.1 Gene amplifications at the locus 4q12  
PDGFRA, KIT and VEGFR2 genes are located at the chromosome locus 4q12. Amplification of 
PDGFRA has long been known to be present in some diffuse gliomas, but recently an adjacent gene, 
KIT, was found to be amplified in some glioblastomas and paediatric osteosarcomas, although no 
activating mutations of KIT were reported (Entz-Werle et al. 2007, Sihto et al. 2005). PDGFRA is 
thought to be amplified as Dmins (Muleris et al. 1994), and recent findings suggest that in 
glioblastomas the amplified region may include a number of adjacent genes at the 4q12 locus 
(Holtkamp et al. 2007). In adult and adolescent seminomas KIT amplification has been accompanied 
with mutations in KIT exon 17 (McIntyre et al. 2005), and PDGFRA and VEGFR2 were also 
occasionally co-amplified. Based on genome-wide mapping of genetic alternations in human gliomas, 
the glioma phenotype may in part reflect its gene amplification and expression profiles (Bredel et al. 
2005). 
 
 
Figure 6. Chromosome 4 showing the location of PDGFRA, KIT and VEGFR2.  
4. Angiogenesis in gliomas 
Tumors may produce pro-angiogenic proteins to overcome hypoxia, which results in activation of the 
transcription factor HIF-1-α (hypoxia inducible transcription factor-1-alpha). This induces expression 
 
p- arm
q- arm
CHROMOSOME 4
PDGFRA
KIT
VEGFR2
4q12Centromere
  32 
of VEGF and results in activation of genes that are involved in angiogenesis induction (Carmeliet et 
al. 1998, Kerbel & Folkman 2002, Lohela et al. 2009, Semenza 2003, Shweiki et al. 1992). VEGF 
and other proangiogenic factors are required for blood vessel and tumour growth, but tumour 
angiogenic activity may not always reflect its biological aggressiveness (Bergers et al. 2003). 
 
ANG-1 (angiopoietin-1) is a ligand of the TIE-2 RTK that is expressed on endothelial cells. It 
interacts with other angiogenic molecules to stabilize the vascular structures by promoting survival of 
differentiated endothelial cells (Audero et al. 2001, Hanahan 1997, Oliner et al. 2004, 
Papapetropoulos et al. 1999, Yancopoulos et al. 2000, Saharinen et al. 2010). ANG-2 is an antagonist 
ligand for TIE-2 in endothelial cells, and like VEGF-A, it is produced under hypoxic conditions 
trough induction by HIF  (Maisonpierre et al 1997, Pouyssergur et al. 2006). Initiation of vascular 
sprouting requires destabilization of capillaries, an action mediated by ANG-2 and ANG-1/TIE-2 
signalling, which allows VEGF-A-induced cell migration and division (Pouyssegur et al. 2006). 
Hypoxic stress also leads to attenuation of protein synthesis by regulating the mTOR and other 
pathways (Pouyssegur et al. 2006). 
 
Some diffuse astrocytic tumors, especially primary glioblastomas, may grow fast, which may lead to 
tissue hypoxia and tumour necrosis. VEGF is an important angiogenic factor also in gliomas. 
Glioblastomas are typically highly vascular, and VEGF-A, VEGFR-1 and VEGFR-2 are upregulated 
and phosphorylated in the tumour vasculature (Carroll et al. 1999). VEFG is expressed in the 
palisading tumour cells around necrotic areas and around tumour vessels that express VEGFR-1 and 
VEGFR-2 (Berkman et al. 1993, Hatva et al. 1995, Plate et al. 1994a, Plate et al. 1994b, Plate & 
Mennel 1995, Plate & Risau 1995, Samoto et al. 1995, Shweiki et al. 1992, Takano et al. 1996). 
VEGFR-2 is expressed not only in the vascular endothelia of glioblastoma, but sometimes on the 
glioblastoma cells as well (Steiner et al. 2004). Astrocytomas first depend on the existing normal 
brain blood vessels, but with further tumour growth hypoxia induce angiogenesis via HIFs, VEGFs, 
VEGFR-2 and ANG-2 (Bergers & Benjamin 2003).  
 
Although pilocytic astrocytomas differ greatly from their malignant counterparts, they also have a 
high blood vessel density. Pilocytic astrocytomas show features of more mature, stable, thick and 
multi-layered vessels compared to anaplastic astrocytomas. In pilocytic astrocytomas VEGFR-2 and 
VEGFR-1 are expressed in the tumour vasculature in coiled young proliferating vessels together with 
VEGF. This suggests presence of a paracrine loop. Unlike diffuse gliomas, progressing pilocytic 
astrocytomas do not develop the characteristic necroses with palisading tumour cells (Gesundheit et 
al. 2003, Haapasalo et al. 1999, Leung et al. 1997, Takeuchi et al. 2004). 
 
PDGF and its receptors are also important for angiogenesis. PDGFRs are expressed in several cell 
types, and PDGFRA, for example, in the vascular smooth muscle cells and megakaryocytes. PDGF 
has some angiogenic effect, and its role in wound healing is evident (Heldin & Westermark 1999). 
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Angiogenesis may be assisted by homing of bone marrow-derived cells on the developing vessels. 
Cells of hematopoietic origin have been reported to navigate they way to the sites where new blood 
vessels are formed and contribute to neovascularization, and express endothelial cell markers such as 
E-cadherin, VEGFR-1, VEGFR-2 and TIE-2 (Bertolini et al. 2006, Conejo-Garcia et al. 2005, De 
Palma et al. 2005, Grunewald et al. 2006, Okazaki et al. 2006, Venneri et al. 2007). The putative 
cancer stem cells of brain tumors might localize close to an adjacent blood vessel (Asahara et al. 
1997, Calabrese et al. 2007). However, the mechanisms by which bone marrow-derived stem cells 
might contribute to angiogenesis are incompletely understood, the origin of neovascular endothelial 
cells are controversial and some recent results suggest that bone marrow-derived circulating 
endothelial precursors do not contribute to vascular endothelium and are not needed for tumour 
growth (Purhonen et al. 2008). 
 
Besides the VEGF/ VEGFR pathway, hypoxic conditions may promote expression of the genes 
involved in oxygen supply and tissue maintenance. Secretion of the SCF and signalling via the KIT-
AKT pathway has been implied under hypoxia (Berdel et al. 1992, Cockman et al. 2000, Erlandsson 
et al. 2004, Jin et al. 2002, Jogi et al. 2002, Litz & Krystal 2006, Ohh et al. 2000, Sihto et al. 2007).  
KIT may have a role in angiogenesis as well. SCF-KIT signalling enhances tube formation of 
developing capillary vessels (Matsui et al. 2004). KIT is expressed during ontogenesis in the alveolar 
capillaries and in capillary endothelia of the placenta (Miettinen et al. 2000). KIT may be expressed 
in tumour endothelial cells, and endothelial cells of primary glioblastomas were recently found to 
express KIT frequently (Sihto et al. 2007). The functional role of endothelial cell KIT remains 
speculative, but in pathological angiogenesis activated KIT may recruit endothelial progenitors to the 
inflamed endothelium (Dentelli et al. 2007). Little is known about endothelial cell KIT expression in 
lower grade gliomas and other CNS tumors. 
5. RTK activation and targeted therapies 
RTKs are activated upon ligand binding and formation of homo- or heterodimers, and consecutive 
trans-autophosphorylation (Blume-Jensen & Hunter 2001). Certain tyrosine amino acid residues in 
the RTK kinase domain serve as phosphoacceptors activating the receptor by a conformational 
change. Autophosphorylation of one or two homologous juxtamembrane tyrosine residues is required 
for full kinase activation in RTKs, and a mutation of a critical codon encoding a tyrosine residue to, 
for example, a phenylalanine encoding residue may significantly reduce the kinase activation (Blume-
Jensen & Hunter 2001, Hashimoto et al. 2003, Pawson & Scott. 2005, Ueda et al. 2002). 
 
Several ATP-mimetic drugs are currently being used in cancer therapy, and many more are being 
developed. Imatinib mesylate was the first small molecule RTK inhibitor that was approved for 
cancer treatment, first for CML and later for GIST. Imatinib is a selective inhibitor of KIT, PDGFRA, 
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PDGFRB, BCR-ABL, ABL, ARG and c-fms (Capdeville et al. 2002, Desjardins et al. 2007, Druker 
et al. 2006).  
 
KIT is activated notably in GISTs due to mutations as discussed above (1.3.1). Most GISTs are highly 
responsive to imatinib, in particular those that harbour mutation in KIT exon 11 (Heinrich et al. 
2003). Imatinib is now the standard treatment of advanced GIST (Joensuu 2006), and it is now 
approved also for adjuvant treatment of high-to-moderate risk GIST patients (DeMatteo et al. 2009). 
KIT mutations (D816V) are found also in mastocytosis, some cases of acute myeloid leukemia 
(Fritsche-Polanz et al. 2010) and seminomas (McIntyre et al. 2005). Recently, KIT mutations and 
amplifications were found also in 10 to 40% of mucosal and acral melanomas, and in some 
melanomas located in sun-exposed sites. Interestingly, many of these melanomas respond to imatinib 
and other RTK inhibitors (Handolias et al. 2010). However, many human tumour types that express 
KIT in immunohistochemistry do not contain activated or mutated KIT, and KIT 
immunohistochemistry is inadequate in selection of patients for targeted therapy (Sihto et al. 2005).  
 
Small molecule oral tyrosine kinase inhibitors have recently been studied in the treatment of 
glioblastoma, but the success has remained limited. The agents tested include inhibitors of the EGFR, 
such as gefitinib (Franceschi et al. 2007, Uhm et al. 2010), and inhibitors of the PDGFRs and KIT, 
such as imatinib (Dresemann et al. 2010). Factors that limit efficacy of tyrosine kinase inhibitors may 
include pharmacological factors, such as poor drug penetration into the CNS, and early development 
of drug resistance (Mellinghoff et al. 2005), but tumour heterogeneity might also have a role.  
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AIMS OF THE STUDY  
 
To study EGFR mutations and their association with EGFR amplification in various histological 
types of human cancer, including brain tumors (I). 
 
To investigate amplifications of KIT, PDGFRA, VEGFR2 and EGFR genes and their mutations in 
glioblastoma (II). 
 
To investigate amplifications of KIT, PDGFRA, VEGFR2 and EGFR genes in low grade glioma, 
anaplastic astrocytoma and their recurrences (III).  
 
To evaluate KIT and VEGFR2 expression in endothelial and tumour cells in paediatric brain 
tumors, and to investigate KIT gene copy numbers in these tumors (IV). 
 
To study the heterogeneity of EGFR and KIT gene amplification and their protein products in 
gliomas and glioblastoma (V). 
 
MATERIALS AND METHODS 
1. Patients and tumour samples 
The tissue diagnoses in the current studies were made by a professional pathologist, who also selected 
the tumour samples and ascertained their representativeness from hematoxylin and eosin stained 
slides. The following series were studied: 
 
(I) Tumour tissues from a series of 560 neoplasms consisting of several histological types of 
tumors were selected at random from the archives of the Departments of Pathology, 
Helsinki University Central Hospital, Tampere University Central Hospital, and the 
Institute of Medical Technology, University of Tampere. In addition, tumour samples 
from six NSCLC patients treated with gefitinib were analyzed.  
 
(II) Formalin-fixed paraffin-embedded tumour tissue from 48 patients who underwent 
craniotomy for a brain tumour and who were subsequently diagnosed with glioblastoma 
multiforme at the Department of Pathology, Helsinki University Central Hospital, 
between October 2000 and December 2003.  
 
(III) Formalin-fixed paraffin-embedded tumour tissue from 119 patients who had craniotomy 
for a primary glioma in 1979 to 2000, and who had brain tumour tissue available for 
analysis both from the primary tumour and its recurrence, were retrieved from the 
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archives of the Department of Pathology, Helsinki University Central Hospital. The 
tumors were originally diagnosed as diffuse astrocytoma (grade 2, 3 or 4), 
oligodendroglioma (grade 2 or 3) or oligoastrocytoma (grade 2 or 3). 
 
(IV) Formalin-fixed, paraffin-embedded tissue was retrieved from 35 patients with juvenile 
pilocytic astrocytoma diagnosed at the age of 18 or younger, and from 49 paediatric brain 
tumors consisting of various histological types diagnosed at the Helsinki University 
Central Hospital, Helsinki, Finland, in 1985 to 2007. Samples containing histologically 
normal tissue of several organs (n=16) were collected from aborted fetuses, from 
autopsies and from surgical operations. Fetal samples from fetuses younger than 20 
weeks were obtained from spontaneous or induced abortions performed by the treating 
obstetricians according to the Finnish law at the Turku University Central Hospital. Other 
fetal samples were from stillbirths. The non-neoplastic and dysplastic cortical and 
subcortical tissues from brain resection for epileptogenic lesions were retrieved at random 
from the archives of the Department of Pathology, Helsinki University Central Hospital, 
Finland. 
 
(V) Brain tumour tissue from 22 patients who underwent craniotomy and extensive resection 
at the Helsinki University Central Hospital (HUCH), Helsinki, Finland, in 1998 to 2006 
was used as the starting material in the study. Since we investigated tumour 
heterogeneity, we required that five or more tumour tissue blocks were available for 
analysis at a computerized search of the files of the Department of Pathology, HUCH. 
Otherwise, the tumors were selected at random for the study. 
2. Tissue microarray (III) 
Routinely fixed paraffin-embedded tumour samples of representative tumour regions were used for 
construction of tumour tissue microarray (TMA) blocks, each containing approximately 100 tumour 
samples. Five µm sections were cut from the TMAs and processed for immunohistochemistry. 
3. Polymerase chain reaction (I-III) 
Fifty nanograms of the genomic DNA was amplified in a polymerase chain reaction (PCR) reaction 
containing 0.6 x Platinium PCR Buffer (Invitrogen), 1.4 to 2.4 µM of MgCl2, 160 µM of dNTPs 
(Clontech), 0.3 µM of forward and reverse primers, and DNA polymerases AmpliTaq Gold (Applied 
Biosystems), and Platinium Taq (Invitrogen) in a volume of 50µL. The PCR cycling conditions 
consisted of an initial denaturation step at 94°C for 14 minutes, after 35 cycles at 94°C for 30 
seconds, annealing (annealing temperatures in Table 2) for 45 seconds and 2 minutes at 72°C, and 
final extension for 10 minutes at 72°C. Heteroduplex formation was created by denaturing the PCR 
products for 5 minutes at 95°C and then allowing the samples to reanneal by decreasing the 
temperature 1°C per minute from 95°C to 40°C.  
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4. Denaturing high-performance liquid chromatography (I-III) 
Denaturing high-performance liquid chromatography (DHPLC) is a high-throughput mutation-
screening method (Xiao & Oefner 2001). In this technique, a PCR amplicon from the target gene is 
denatured in order to separate the existing homoduplexes and then allowed slowly to cool (reanneal). 
This results in formation of both homo- and heteroduplexes. The DHPLC running temperature is 
carefully selected so that partial denaturation begins to occur in the area around the polymorphic 
mismatch. Heteroduplexes elute before the homoduplexes in a specifically designed dsDNA HPLC 
column. DHPLC has the sensitivity for detecting genetic changes in heterogeneous cell populations, 
e.g. mutant cells within their normal cell background/contamination. Five to 10 µL of the PCR 
product was injected on the HPLC Column and eluted at a flow rate of 0.45 mL/min within a linear 
acetonitrile gradient consisting a mixture of buffer A (100mmol/L triethyl ammonium acetate and 0.1 
mmol/L EDTA; Varian), and buffer B (100 mmol/L triethyl ammonium acetate, 0.1 mmol/L EDTA 
and 25% acetonitrile; Varian). PCR products from normal DNA were used as controls. The elution 
temperatures for each amplicon were obtained from the DHPLC Melt Program 
(http://insertion.stanford.edu/melt.html) and then optimized by studying alterations in the elution 
profiles of the samples within a temperature range of 2°C under and above the suggested melting 
temperature. The temperature that best separated homoduplexes was used for DHPLC analysis.  
 
Table 2. The used primer sequences and the annealing temperatures for different genes and 
their exons, and the elution temperatures used in DHPLC analyses. 
GENE  Primer sequences (5'->3')  Temperature (°C) 
Study (I) Exons Forward Reverse Annealing Elution 
EGFR 4 GCTTAATTGCGGGACTCTTGT TAGAGCTGTCCCCCATAGGA 57  
EGFR 4.2 AAAGAGTGCTCACCGCAGTT CATAGGAGCTGGAGGCAGAG 57 62 
EGFR 5 AGCCAGCCAAACAATCAGAG CCACCCTGGATTAACTGCAT 57  
EGFR 5.2 GAAAGGGCGTCATCAGTTTC TTTGGAGTCTTCAGAGGGAAAA 57 58 
EGFR 6 CCCTGGGAAATGATCCTACC AAGTCTTCTGTCCTGGTGTGG 56  
EGFR 6.2 CAGGGAACCTTTGCTCTTTTT CAGCCTGCTCCAGGGAGG 59 63 
EGFR 7 GCTGAGTGTACTTACCTCAC GGACAAGGATGCCTGACCAG 61  
EGFR 7.2 CCAGCGTGTCCTCTCTCCT CAGTTAGAGGGCCCACAGAG 59 62 
EGFR 8 CTTTCCATCACCCCTCAAGA CTCAGCAGCCGAGAACAAG 59  
EGFR 8.2 CACCGTCATCACCTTCCTTT CCGAGAACAAGCCTCGTC 60 62 
EGFR 12 TCAATCAAAGGTGGTCTGGA GGACCCATTAGAACCAACTCC 57  
EGFR 12.2 TCTGGAGAAACAAAGTTTTCAGG AAACAGAAGCGGTGACTTACT 61 57 
EGFR 13 CATGTCTGTGTCACCCAAGG CAGAAAACCCAAAACCTCCA 61 57 
EGFR 14 GGTGATTTGTGTTCCTGCAA TCATCACTGTTCGGCTTCTG 57  
EGFR 14.2 CTGACGGGTTTCCTCTTCCT CCCTTCCCATGAAATGGAC 57 61 
EGFR 15 ATCATTTGGCTTTCCCCACT ATTTGTTGCCGGAAAACTTG 59  
EGFR 15.2 GCATGAACATTTTTCTCCACCT TGAATTTGCAAGAGAGGAAATG 59 60 
EGFR 17 CATGGAATCTGTCAGCAACC ACATACACAACTGCTAATGG 56 58 
EGFR 18 CAAATGAGCTGGCAAGTGCCGT GAGTTTCCCAAACACTCAGTGA 61  
EGFR 18.2 CAAGTGCCGTGTCCTGGCACCCAAGC CCAAACACTCAGTGAAACAAAG 52 58 
EGFR 19 GGCACCATCTCACAATTGCC CCCCACACAGCAAAGCAGAA 57  
EGFR 19.2 TGCCAGTTAACGTCTTCCTTC CCACACAGCAAAGCAGAAAC 60 59 
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EGFR 21 CACTAACGTTCGCCAGCCAT CTCCCCTGCATGTGTTAAAC 61  
EGFR 21.2 CACTAACGTTCGCCAGCCAT CCTGGTGTCAGGAAAATGCT 60 63 
EGFR 23 CATTCATGATCCCACTGCCT CAAGGCTCAGCTAGGCAGT 52 60 
Study (II)      
EGFR 18 CAAATGAGCTGGCAAGTGCCGTGT GAGTTTCCCAAACACTCAGTGAAA 56  
EGFR 18.2 CAAGTGCCGTGTCCTGGCACCCAAGC CCAAACACTCAGTGAAACAAAGA 56 56 
EGFR 19 GGCACCATCTCACAATTGCC CCCCACACAGCAAAGCAGAA, 56  
EGFR 19.2 TGCCAGTTAACGTCTTCCTTCTC CCACACAGCAAAGCAGAAACTC 56 58 
EGFR 21 CACTAACGTTCGCCAGCCATA TGTTTAACACATGCAGGGGAG, 56  
EGFR 21.2 CCTCACAGCAGGGTCTTCTCT CAGCATTTTCCTGACACCAGG 56 60 
Study (II)      
KIT 9 GTATGCCACATCCCAAGTGT CATGACTGATATGGTAGACA 57 57 
KIT 11 CCAGAGTGCTCTAATGACTG GGAAGCCACTGGAGTTCCTT 57 57 
KIT 13 GACATCAGTTTGCCAGTTGT TGTTTTGATAACCTGACAGAC 57 58 
KIT 17 GCAACACTATAGTATTAAAAAG CCTTTGCAGGACTGTCAAGCA 57 57 
Study (II)      
PDGFRA 11 ATGTGGAGTGAACGTTGTTGG CTAGTTCTTACTAAGCACAAGC 57 59 
PDGFRA 17 CAGGGGTGATGCTATTCAGC TTAAAGTGAAGGAGGATGAGCC 60 59 
Study (III)      
TP53 6 AGGGTCCCCAGGCCTCTGAT CCACTGACAACCACCCTTAA 58 62 
TP53 7 TGCTTGCCACAGGTCTCC TGTGCAGGGTGGCAAGTGGC 64 62 
TP53 8-9 AGTAGATGGAGCCTGGTTTTT RAGAAAACGGCATTTTGAGTG 63 63 
 
5. DNA sequencing (I-III) 
Samples with an abnormal elution profile (eluation peak shape or shift in eluation time deviating from 
normal control sample) in DHPLC compared with a control consisting of lymphocyte DNA were 
subjected to automated sequencing located at Biomedicum Helsinki. The PCR products were first 
purified, using a QiAquick PCR purification kit (Qiagen). Direct sequencing of the PCR products was 
performed using BigDye3 termination chemistry (Applied Biosystems) and an ABI 3100 Genetic 
Analyser (Applied Biosystems).  
6. Fluorescence in situ hybridization (I-III) 
Centromere-specific probes for chromosomes 4 and 7 (CEP4 and CEP7, Spectrum Green, Vysis) 
were purchased, and the gene copy numbers were determined using BAC (bacterial artificial clones) 
probes for KIT (clone RP11-586A2), PDGFRA (clone RP11-231C18), VEGFR2 (clone RP11-
662M13) and EGFR (clone RP11-815K24) (Invitrogen). The correct probe identity was confirmed 
using specific PCR-primers for each gene. The BAC DNA was isolated using standard techniques, 
and labeled with the digoxigen-nick and biotin-nick translation mix (Roche). Interphase nuclei were 
prepared using standard techniques and viewed under a fluorescence microscopy equipped with an 
ISIS digital image analysis system (MetaSystems). Dual-color hybridizations were performed. After 
hybridization the probes were detected immunochemically with avidin-fluorescein isothiocyanate and 
anti-digoxigenin rhodamine, and the slides were counterstained with 0.1 µmol/L 4,6-diaminido-2-
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phehylindole in an antifade solution. Signal copy numbers were counted approximately from 50 
randomly chosen non-overlapping nuclei.  
7. Chromogenic in situ hybridization (III-V) 
Whole tissue sections of 3µm mounted on glass slides were deparaffinized and incubated in 0.05M 
Tris-HCl/ 0.001M EDTA solution (pH 9) in a temperature controlled microwave oven (at +92°C for 
10 minutes), followed by cooling down for 20 minutes at room temperature. After wash with H2O, 
enzymatic digestion was carried out by applying 100µL of 10µg/µL proteinase K (Roche) in 2mM 
CaCl2/ 20mM TRIS solution on to tissue sections for 10 to 20 minutes at room temperature or +37°C 
following with wash with H2O and dehydration with an ascending gradient of ethanol. Digoxigen-
labelled BAC probes were prepared as described above and applied onto slides. Sections were 
denatured in the presence of BAC probes on a heat plate (+75°C to +85°C). Hybridization was 
expected to occur during over night incubation at +37°C. After incubation the slides were washed 
with 0.5xSSC for 5 minutes at +75°C followed by PBS wash. The probes were detected by FITC-
sheep anti-digoxigen, HRP-goat anti-FITC and DAB chromogen according to the manufacturer’s 
protocol (Spot-Light CISH detection kit, Zymed). Alternatively, the enzymatic digestion was carried 
out by applying 100 µL of digestion enzyme onto the slides for 10 to 15 min at room temperature 
(Digest-All III solution, Zymed), and the probes were detected with a mouse anti-digoxigenin 
antibody (diluted 1:300; Roche Biochemicals, Mannheim, Germany), an antimouse-peroxidase 
polymer (Powervision+, ImmunoVision Technologies), and diaminobenzidine chromogen according 
to the manufacturer’s protocol. Tissue sections were counterstained with hematoxylin. Gene 
amplification was considered to be present when six or more signals or clusters of signals in one 
nucleus were detected in more than 10% of the counted nuclei. Cases with three to five signals per 
nucleus were considered as aneuploid and those with 2 signals as diploid (normal).  
8. Immunohistochemical staining (II-V) 
Five µm tissue sections were cut and mounted on glass slides. Tissue sections were deparaffinized 
and examined for KIT (CD117), phosphorylated KIT, SCF, PDGFRA, VEGFR2, HIF-1-alpha, 
EGFR, EGFRvII, phosphorylated EGFR, TP53, Ki67, CD34, nestin and prominin 1 (CD133). The 
primary antibodies were diluted in PowerVision pre-antibody blocking solution and incubated 
overnight at 4 ◦C. Binding of the primary antibody was detected with a Powervision+ Poly-HRP 
histostaining kit (Immunovision Technologies), using an Envision Detection KIT (Dako) or with the 
Ultravision Immunohistochemical Detection System (Lab Vision). The antibodies used, their dilution 
concentrations, pre-treatment buffers and the heat pre-treatments given are listed in Table 3. Tissue 
samples with known expression of the studied protein were used as positive controls. The 
immunostainings were graded as negative (-), faintly positive (+), moderately positive (++), or 
markedly positive (+++) when viewed under a consultation microscope (Nikon Eclipse E600). 
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Table 3. A list of antibodies and their dilution concentrations, pre-treatment buffers and heat 
pre-treatments used. 
Target protein 
(study) 
Antibody used Dilution Pre-treatment buffer Heat pre-treatment 
EGFR (II, III, IV) 
 
Mouse monoclonal NCL-
EGFR (Novocastra) 
1:150 
(II) and (III) Reveal buffer (Biocare 
Medical); (IV) 10mmol/L Sodium-
citrate buffer, pH 6 
Autoclave at 120 ◦C, 
2 min 
 EGFRvIII (II,IV) 
Mouse monoclonal NCL-
EGFRT (Novocastra) 
1:200 Reveal buffer (Biocare Medical) 
Autoclave at 120 ◦C, 
2 min 
phosphorylated EGFR 
(II) 
Monclonal mouse anti-
EGFR (My10; BD 
Biosciences) 
1:100 TRIS-EDTA, pH 9 
Microwave owen 
7min and 3x5 min, 
850W 
KIT (CD117) (II-IV) 
 
Polyclonal rabbit anti-
CD117 (A 4502; DAKO) 
1:300 
(II) and (III) TRIS-EDTA, pH 9; (IV) 
10mmol/L Sodium-citrate buffer, pH 
6 
(II) Microwave owen 
7min and 3x5 min, 
850W; 
(III) 98°C waterbath, 
15 min 
phosphorylated KIT (IV)  
Phospho-c-KIT (Tyr719) 
(#3391, Cell Signaling) 
1:35 
10mmol/L Sodium-citrate buffer, pH 
6 
98°C waterbath, 15 min 
SCF (IV) 
Rabbit polyclonal SCF 
(#2273 Cell Signaling) 
1:200 
10mmol/L Sodium-citrate buffer, pH 
6 
Autoclave at 120 ◦C, 
2 min 
PDGFRA (II) 
Polyclonal rabbit anti-
PDGFRalpha Ab-1 (RB-
1691; NeoMarker) 
1:150 Citrate buffer, pH 6 
Microwave owen 
2x4min, 850W 
VEGFR2 (III,IV) 
An epitope specific rabbit 
anti-VEGFR2 (Flk-1 Ab-1, 
Neomarkers) 
1:100 
10mmol/L Sodium-citrate buffer, pH 
6 
Autoclave at 120 ◦C, 
2 min 
Nestin (III) 
Mouse monoclonal anti-
nestin antibody (clone 
10C2, Chemicon 
International) 
1:500 
10mmol/L Sodium-citrate buffer, pH 
6 
Autoclave at 120 ◦C, 
2 min 
Prominin-1 (CD133)(III) 
Mouse anti-human CD133 
antibody (AC133 pure, 
Miltenyi Biotec) 
1:10 
10mmol/L Sodium-citrate buffer, pH 
6 
Autoclave at 120 ◦C, 
2 min 
CD34 (II) 
Monclonal mouse anti-
CD34 (BD Biosciences) 
1:50 TRIS-EDTA, pH 9 
Microwave owen 7min 
and 3x5 min, 850W 
Ki67 (II) 
Mouse monoclonal 
NCL-Ki67-MM-1 
(Novocastra) 
1:1000 
Reveal buffer (Biocare Medical, 
Walnut Creek, CA) 
Autoclave at 120 ◦C, 
2 min 
HIF-1-alpha (IV) 
Monoclonal mouse anti- 
HIF-1α antibody 
(Neomarkers) 
1:100 
10 mmol/L Sodium-citrate buffer, pH 
6 
98°C waterbath, 
20 min 
TP53 (II,III) 
Mouse monoclonal NCL-
P53-DO7 (Novocastra) 
1:500 
Reveal buffer (Biocare Medical, 
Walnut Creek, CA) 
Autoclave at 120 ◦C, 
2 min 
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9. Locked nucleic acid mRNA in situ hybridization for KIT (IV) 
Digoxigenin-labeled locked nucleic acid probes (LNATM mRNA, Exiqon, Inc., Woburn, MA. USA) 
were designed against the KIT extracellular domain coding sequence 5’-gttgagaagagcctgtctggac-3’. 
Efficacy of hybridization was controlled with a polyT(25)Vn probe (LNATM, Exiqon) against a 
poly(A) tail. In situ hybridization was carried out as described earlier with minor modifications 
(Parikka et al. 2001). All reagents and instruments were treated either with diethyl pyrocarbonate 
(DEPC) or were RNAse-free. The sections were counterstained with 0.1% Nuclear Fast Red (Sigma-
Aldrich Inc., Saints Louis, Missouri, USA). The hybridization results were graded as negative (-) or 
positive (+). Glioblastomas with known endothelial cell KIT expression in the tumour vasculature 
served as a positive control. 
10. Statistical analyses (I-V) 
Frequency tables were analyzed using the χ2 test or Fisher’s exact test, and non-normal distributions 
between groups were compared using the Kruskal–Wallis or Mann-Whitney tests. Life-tables were 
computed using the Kaplan–Meier method. The log-rank test was used to compare time-to-event 
distributions. Overall survival was computed from the date of the diagnosis to death, and the patients 
alive were censored on the last date of follow-up. All p-values are two-sided. Statistical analyses were 
computed with either a Statview or an SPSS computer program. 
11. Ethical aspects (I-V) 
The tissue samples analyzed were originally collected for diagnostic or therapeutic purposes, and left-
over tissue was used for the current studies after obtaining permission from the National Authority for 
Medicolegal Affairs (NAM) and an Institutional Ethics Committee. All clinical data were processed 
anonymously using a unique study identity code number for each sample and/or patient.    
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RESULTS  
 
The main findings of the thesis are summarized below (a more detailed description of the results are 
available in the attached Studies I to V).  
1. KIT, PDGFRA, VEGFR2 and EGFR amplifications in primary and secondary 
glioblastomas (II) 
Forty-three primary glioblastomas were analyzed for KIT, VEGFR2, PDGFRA and EGFR 
amplification using fluorescence in situ hybridization. KIT was amplified in 47% and VEGFR2 in 
39% of the glioblastomas, respectively, and PDGFRA in 29%. Thirty-five (81%) of the tumors had 
either KIT or EGFR amplification. KIT, PDGFRA and VEGFR2 amplifications were strongly 
associated (p < 0.0001 for each pair wise comparison) suggesting co-amplification, whereas no 
significant association was found with presence of EGFR amplification. Glioblastomas with KIT, 
PDGFR or VEGFR2 amplification were associated with similar outcome as other glioblastomas. 
 
The four secondary glioblastomas arising from pre-existing lower grade astrocytic tumors 
investigated had each KIT amplification. None of the four analyzed secondary glioblastomas had 
amplified EGFR as compared with 30 (70%) out of the 43 primary glioblastomas (p = 0.013). Three 
out of the four secondary glioblastomas harboured PDGFRA amplification, and one had VEGFR2 
amplification.  
2. KIT, PDGFRA, VEGFR2 and EGFR amplifications in diffuse grade 2 and 3 gliomas 
and their recurrences (III) 
KIT and PDGFRA amplifications were more frequent in anaplastic astrocytomas as compared to 
astrocytomas, oligodendrogliomas and oligoastrocytomas [28% versus 5% (p = 0.012) and 33% 
versus 2% (p = 0.0008), respectively]. VEGFR2 amplifications occurred in 6% to 17% of the grade 2 
or 3 gliomas at diagnosis, and EGFR amplification in 0% to 12%. Amplified KIT was more 
frequently present in recurrent gliomas than in newly diagnosed gliomas (p = 0.0066).  
 
KIT amplification was associated with KIT protein expression and with presence of PDGFRA and 
EGFR amplifications both at the time of the first glioma diagnosis and at tumour recurrence, and with 
VEGFR2 amplification at tumour recurrence. Three (4%) primary gliomas and 10 (14%) recurrent 
gliomas that were evaluable for co-amplification of KIT, PDGFRA and VEGFR2 showed 
amplification of at least two of these genes; the amplicon contained amplified KIT in all 13 cases. In 
addition to astrocytomas, amplification of KIT, PDGFRA and VEGFR2 was found frequently in 
recurrent oligoastrocytic tumors (in 23-33% of the cases). 
 
The effect of gene amplifications on survival was investigated. Since gene amplifications tended to be 
associated with a low grade of glioma differentiation, KIT, PDGFRA, VEGFR2 and EGFR 
amplifications were added as cofactors in a multivariate model that contained the histologic type of 
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glioma as another cofactor. Presence of KIT amplification tended to be associated with unfavourable 
survival based on this multivariate model that accounted for the histologic type of glioma (hazard 
ratio, 2.0; 95% confidence interval, 0.9-4.4; p = 0.075), whereas presence of PDGFRA and VEGFR2 
amplification was not associated with outcome in the model (p = 0.58 and p = 0.11, respectively). 
3. Copy number analysis of KIT in paediatric brain tumors (IV) 
KIT copy number was assessed using CISH in 9 pilocytic astrocytomas. None of the tumors had 
amplification of the gene. Two tumors showed KIT aneuploidy (three to five copies of KIT were 
present per one cell). 
4. Heterogeneity of EGFR and KIT amplifications in gliomas and glioblastomas (V). 
EGFR was amplified in 10 (67%) out of the 15 glioblastomas when only one (index) tissue block 
from each tumour was studied, whereas 11 (73%) glioblastomas were classified EGFR-amplified and 
the rest EGFR aneuploid when all blocks available were considered. KIT was amplified in six (40%) 
index glioblastoma tissue blocks, but in 10 (67%) when all blocks were analyzed. None of the seven 
astrocytomas contained amplified EGFR and only one harboured amplified KIT even when all blocks 
were examined.  
Table 4. A summary of copy number analysis of astrocytic tumors (II, III, IV, V) 
  
Gene and the frequency of amplifications found (%) 
Tumour type  
Studied 
samples 
(n) 
PDGFRA KIT VEGFR2 EGFR 
Astrocytoma grade II (III) 38 3 6 14 0 
Astrocytoma grade II (V) 5 NA 0 NA 0 
Anaplastic Astrocytoma (III) 18 33 28 17 12 
Anaplastic Astrocytoma (V) 2 NA 1 NA 0 
Secondary Gliobalstoma (III) 16 31 36 12 14 
Primary Gliobalstoma (II) 43 29 47 39 70 
Primary Gliobalstoma (V) 15 NA 67 NA 73 
Pilocytic astrocytoma (IV) 9 NA 0 NA NA 
 
Figure 7. Glioma nuclei that present 
aneuploid copy numbers of the genes 
KIT and PDGFR detected by 
fluorescence in situ hybridization. Red 
signals are for KIT gene and green 
signals are for PDGFRA gene. 
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5. KIT, PDGFRA and EGFR mutations in primary and secondary glioblastomas (I, II) 
Among the primary (n=43) and secondary (n=4) glioblastomas subjected to mutation screening, no 
mutations were detected with denaturing high-performance liquid chromatography in KIT exons 9, 
11, 13 or 17, PDGFRA exons 12 or 18, or EGFR exons 18, 19 or 21 (II).  
 
One mutation in an exon coding domain IV of EGFR was found in one out of the 57 glioblastomas in 
study I. This was a missense mutation C624F (substitution of cysteine by phenylalanine at the 
nucleotide position 1,871) in EGFR exon 15 (I). 
 
Brain tumors are the topic of the present thesis, but we investigated in Study I also other tumors than 
brain tumors for presence of EGFR mutations. In brief, we found no EGFR kinase domain mutations 
in glioblastomas, but EGFR kinase domain mutations were found in lung adenocarcinomas and 
bronchioloalveolar carcinomas, of which 8 (11%) out of 73 tumors had a mutation. Six out of the 
eight mutations detected were in-frame deletions in exon 19, and two were leucine to arginine 
substitutions (L858R) at amino acid position 858 in exon 21. The deletions were clustered, and in 
each case, the amino acid residues LREA (leucine, arginine, glutamic acid and alanine) located at 
747–750 were deleted. No EGFR kinase domain mutations occurred among the 493 tumors consisting 
of other histological cancer types than lung cancer, suggesting that EGFR kinase domain mutations 
are more common in lung adenocarcinomas and bronchioloalveolar carcinomas than in other types of 
human cancer. 
6. TP53 mutations in diffuse gliomas and their recurrences (III) 
Mutation of TP53 was present at the time of the diagnosis in 11 (29%) of the 38 astrocytomas, five 
(28%) out of the 18 anaplastic astrocytomas, four (20%) out of the 20 oligodendrogliomas and in 
three (27%) out of the 11 oligoastrocytomas studied. TP53 mutations were not detected more 
frequently in recurrent tumors compared to newly detected tumors (p = 0.25); they were present in 
five (29%) out of the 17 recurrent astrocytomas, eight (38%) out of the 21 recurrent anaplastic 
astrocytomas, four (24%) out of the 17 recurrent oligodendrogliomas, seven (44%) out of the 16 
recurrent oligoastrocytomas, and in six (38%) out of 16 secondary glioblastomas studied. We did not 
find any statistically significant associations between presence of TP53 mutations and KIT, PDGFRA, 
VEGFR2 or EGFR amplifications either in the subset of newly diagnosed gliomas or among recurrent 
tumors (p > 0.10 for all comparisons), although TP53 mutations tended to be associated with  EGFR 
amplifications in the subset of recurrent gliomas (p = 0.075). 
7. Protein expression in primary and secondary glioblastomas (II) 
EGFR protein was expressed more commonly in primary glioblastomas that harboured a high-level 
EGFR amplification (91%) than in glioblastomas that lacked such an amplification (91% vs. 60%, 
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respectively, p = 0.019). EGFR amplification was strongly associated with expression of 
phosphorylated EGFR. Fourteen (64%) of the 22 primary glioblastomas with high-level EGFR 
amplification expressed phosphorylated EGFR as compared with only one (5%) out of the 21 tumors 
that lacked high level amplification (p < 0.0001).  
 
EGFRvIII expression was present in six (27%) out of the 22 primary glioblastomas with high-level 
EGFR amplification as compared to none of the rest of the tumors (n=21; p = 0.022). Marked KIT 
protein expression was rare, and occurred in only one out of the 43 primary and one out of 4 
secondary glioblastomas, both of which had high-level KIT amplification. KIT protein expression 
tended to be more common in glioblastomas that had KIT amplification or aneuploidy than in tumors 
with a normal KIT copy number (p = 0.079). KIT, PDGFRA or VEGFR2 amplifications were not 
associated with expression of EGFR, phosphorylated EGFR or truncated EGFR (p > 0.10 for all 
comparisons). Primary glioblastomas that had either KIT, PDGFRA or VEGFR2 amplification tended 
to express Ki67 more often than tumors that lacked the gene amplification (p = 0.098, 0.060 and 
0.097, respectively), whereas no such tendency was found for EGFR amplification (p = 0.49). 
 
All 47 glioblastomas examined expressed the PDGFRA protein. TP53 expression was not associated 
with amplification of any of the four genes (EGFR, KIT, PDGFRA or VEGFR2) in primary 
glioblastomas (p > 0.10 for all comparisons). None of the four secondary glioblastomas expressed 
EGFR as compared to 33 (76%) out of the 43 primary glioblastomas (p = 0.0061), and none 
expressed phosphorylated EGFR or EGFRvIII. Three (75%) out of four secondary glioblastomas, but 
only four (9%) out of 43 primary glioblastomas, expressed TP53 (p = 0.0092). 
8. Expressions of KIT, PDGFRA, VEGFR2 and EGFR protein in diffuse grade 2 or 3 
gliomas and their recurrences (III) 
KIT protein expression was rare in grade 2 or 3 gliomas. Moderate KIT expression was present in 
only one (1%) out of the 87 gliomas at the time of the diagnosis. This was a case of anaplastic 
astrocytoma that harboured KIT gene amplification. Strong KIT protein expression was detected in 
three (3%) recurrent gliomas (n=87); in two (13%) out of 16 secondary glioblastomas and in one 
(6%) out of 18 anaplastic astrocytomas. All recurrent gliomas with strong KIT expression had KIT 
gene amplification, and KIT protein expression was significantly associated with KIT amplification in 
the subset of recurred gliomas (p = 0.018). No associations were found between VEGFR2 protein 
expression and presence of VEGFR2 amplification (p = 0.18), or with EGFR protein expression and 
EGFR amplification (p = 1.00).  
9. Nestin and prominin-1 expression in diffuse grade 2 or 3 gliomas and their 
recurrences (III) 
No association was found between KIT amplification, TP53 mutation and prominin-1 expression (a 
suggested marker for brain stem cells) in the subset of newly diagnosed gliomas (n = 87), and, 
similarly,  no association was present between prominin-1 expression and PDGFRA, VEGFR2 or 
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EGFR gene amplifications (p  > 0.1 for all comparisons). Nestin expression (another protein marker 
of neural stem cells) was associated with presence of TP53 mutations in the subset of recurred 
gliomas. Twenty-five out of the 28 (89%) recurred gliomas that harboured TP53 mutation expressed 
nestin compared with 30 of the 45 (67%) recurred gliomas that did not contain TP53 mutation (p = 
0.029). Nestin expression was not associated with TP53 mutations in the subset of newly diagnosed 
gliomas, and no significant associations were detected between presence of EGFR, KIT, PDGFRA or 
VEGFR2 amplifications and nestin expression. 
10. KIT, phosphorylated KIT, SCF, VEGFR2 and HIF-1-alpha expression in 
endothelial cells of paediatric brain tumors, and in non-malignant fetal and postnatal 
tissues (IV) 
KIT, phosphorylated KIT, SCF and VEGFR-2 expression was studied in 35 juvenile pilocytic 
astrocytomas and 49 other paediatric brain tumors using immunohistochemistry. KIT and phospho-
KIT were moderately or strongly expressed in tumour endothelia of 37% and 35% of pilocytic 
astrocytomas, respectively, whereas marked SCF and VEGFR-2 expression was uncommon. KIT 
mRNA was detected in tumour endothelial cells. Tumour endothelial cell KIT expression was 
strongly (p < 0.01) associated with endothelial cell phospho-KIT and SCF expression, and with 
tumour KIT (p = 0.0011) and VEGFR-2 expression (p = 0.022). KIT and phospho-KIT were 
frequently present in the endothelia of ependymomas (six [55%] out of 11 tumors, and five [45%] out 
of 11 tumors, respectively). Endothelial cell KIT expression was associated with a young age at 
diagnosis of pilocytic astrocytoma or ependymoma, and it was occasionally present in histologically 
normal tissue of the foetus and young children. 
11. Heterogeneity of EGFR EGFRvIII, KIT and phospho-KIT protein expression in 
gliomas and glioblastomas (V). 
In addition to gene copy number heterogeneity, we studied the gene product (protein) heterogeneity in 
15 glioblastomas by examining several tissue blocks from each tumour using immunohistochemistry.  
EGFR, EGFRvIII, KIT and phospho-KIT expression was frequently heterogeneous, and occurred at 
least in a part of the tumour in 93%, 33%, 93% and 100% of the tumors, respectively. Five (70%) out 
of the seven astrocytomas examined in a similar manner for protein expression heterogeneity 
expressed EGFR in a part of the tumour, and three (43%) out of the seven astrocytomas expressed 
KIT suggesting substantial heterogeneity in EGFR and KIT expression in astrocytomas. 
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DISCUSSION 
 
Clinically, gene amplifications have diagnostic and prognostic usefulness, and amplification of 
genomic regions in cancer cells often represent selection of genes that promote tumour growth 
(Albertson 2006). EGFR gene amplification and EGFR protein overexpression have long been 
considered as hallmarks of primary glioblastoma (Reifenberger & Collins 2004).  
 
Glioblastomas often display morphological heterogeneity, where tumour areas that show high 
histological grade of differentiation with well-differentiated cells are commonly found adjacent to 
poorly differentiated areas (Reifenberger & Collins 2004). Such heterogeneity likely exists also at the 
molecular level. Amplification of EGFR is reported to be present in 40-50% of primary 
glioblastomas, where its presence is generally associated with a poor patient outcome (Hurtt MR et al. 
1992, Schlegel J et al. 1994, Riemenschneider MJ et al. 2010). 
 
The present findings are generally in line with a hypothesis that EGFR plays an important role in the 
molecular pathogenesis of primary glioblastoma. EGFR amplification was very frequent and occurred 
in as many as in 70% of the primary glioblastomas studied (II). In addition to EGFR amplification, 
expression of the truncated form of the EGFR protein (EGFRvIII) was common in glioblastoma (II), 
whereas other EGFR mutations turned out to be infrequent (I). Heterogeneity in EGFR amplification 
was more limited as compared to that of KIT amplification in primary glioblastoma (V). EGFR 
protein was commonly expressed in primary glioblastoma, and the protein was frequently activated 
(phosphorylated) (II). Expression of phosphorylated EGFR was strongly associated with EGFR 
amplification (II). Taken together, these findings suggest that EGFR is of importance for the 
development of primary glioblastoma. In contrast, in lower grade gliomas (astrocytoma grade II and 
III) and secondary glioblastomas EGFR amplification was relatively rare and occurred in less than 
15% of the tumors examined (III), suggesting that EGFR is less important in the molecular 
pathogenesis of low grade gliomas and secondary glioblastomas than of primary glioblastomas, and 
that the molecular pathogenesis of these tumors differs from that of primary glioblastoma. 
We found the rate of EGFR amplification may be even higher than previously described in primary 
glioblastomas. The variation in the reported frequency of EGFR amplifications in glioblastoma may 
in part be explained by tumour heterogeneity, and it likely depends also on the proportion of classical 
glioblastomas in the series. We found KIT amplification, and to a lesser extent EGFR amplification, 
to be heterogeneous in glioblastomas (V).  
 
Genes other than KIT or EGFR might be variably amplified at specific sites of a single tumour, and 
their functional activity might also vary within the tumour. More tumour regions with gene 
amplification may thus be identified when the entire tumour tissue is subjected to analysis as 
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compared to analysis of a single tumour biopsy. It may not be possible to assess reliably the 
frequency of gene amplifications from a single tissue biopsy particularly in glioblastomas due to the 
substantial intratumoral heterogeneity. The degree of intratumoral heterogeneity may vary between 
genes and their protein expression in a way that is difficult to predict without careful assessment of 
the entire tumour, which may complicate optimal selection of modern targeted treatments for a 
glioma patient.  
 
The role of KIT, PDGFRA and VEGFR2 in the molecular pathogenesis of primary glioblastomas 
remains less well understood than that of EGFR. The results obtained in this thesis are compatible 
with a hypothesis that amplification of KIT, PDGFRA and VEGFR2 might rather be secondary events 
in tumour progression than a primary cause of glioma. KIT, PDGFRA and VEGFR2 are located 
adjacent on chromosome 4q, and they were frequently coamplified (II). The amplicon frequently 
contained KIT (III). Although amplification of KIT, PDGFRA and VEGFR2 were frequent in primary 
glioblastoma (in particular amplification of KIT, which was found in 47% of the primary 
glioblastomas studied)(II), KIT protein was infrequently expressed in primary glioblastoma, and KIT, 
PDGFRA and VEGFR2 amplifications were not associated with patient survival. KIT expression was 
often heterogeneous in primary glioblastoma (V), which is also compatible with the hypothesis that 
KIT amplification is a secondary event. KIT, PDGFRA and VEGFR2 amplifications tended to be 
associated with a high tumour Ki-67 expression and thus with a high cell proliferation rate.  
 
The hypothesis that primary glioblastomas have a different molecular pathogenesis from secondary 
gliomas and lower grade astrocytomas has recently gained much support following the detection of 
isocitrate dehydrogenase-1 (IDH1) gene mutations (Balss J et al. 2008) in gliomas, and 
characterization of the clinical significance of IDH1 and its related gene IDH2 mutations (Yan et al. 
2009). Presence of IDH1 and IDH2 mutations may now became the key criteria when classifying 
glioblastomas into the primary and the secondary types.  
 
IDH1 and IDH2 encode critical proteins (R132 and R172, respectively) that function in the NADP+-
dependent cellular processes. Mutations of IDH1 are found in more than 70% of WHO grade II and 
grade III astrocytomas and oligodendrogliomas, and in secondary glioblastomas that develop from 
these tumors. Of note, gliomas that lacked IDH1 mutation often harboured a mutation in the IDH2 
gene. Patients with a tumour with either IDH1 or IDH2 mutation had better outcome than patients 
whose glioma harboured wild-type IDH gene (Yan et al. 2009) and mutations in IDH1 occurred in a 
large fraction of young patients and in most patients with secondary GBMs and were associated with 
an increase in overall survival (Parsons et al. 2008). 
 
Importantly, IDH1 and IDH2 mutations are very rare in primary glioblastoma, medulloblastoma, 
pilocytic astrocytoma and ependymoblastoma, and they were not found in any of the 494 non-CNS 
tumors investigated (Yan et al. 2009). These findings suggest that IDH1 and IDH2 mutations are 
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important in the molecular pathogenesis of WHO grade II and grade III astrocytomas, 
oligodendrogliomas and secondary glioblastomas. Mutations IDH1 and IDH2 may occur early in the 
molecular pathogenesis that leads to genesis of these tumour types.   
 
A recent large scale study analyzing DNA copy number, gene expression and DNA methylation study 
provides new insights into the roles of NF1 and TP53 in glioblastomas (Cancer Genomic Atlas 
network 2008). Mutations of TP53 gene, once thought to predominate in secondary glioblastoma, 
have been found at a high frequency also from primary glioblastomas, and NF-1 somatic mutations 
showed new relevance in sporadic glioblastomas. In addition, A recent genomic analysis of 
glioblastomas identified four clinically relevant glioblastoma subtypes based on aberrations of EGFR, 
NF1 and PDGFRA/IDH1 and their gene expression, which resulted in subclassification of 
glioblastomas into the classical, mesenchymal and proneural subtypes (Verhaak et al. 2010). The 
classical glioblastoma subtype was associated with EGFR amplification in as many as 95% of the 
tumors with no alterations in TP53, NF1, PDGFRA or IDH1, whereas the mesenchymal subtype was 
associated with a high frequency of NF1 mutations and deletions, and expression of Schwann cell 
markers such as S100 and microglial markers. The proneural subtype was associated with young age, 
PDGFRA abnormalities, and IDH1 and TP53 mutations, which are features of secondary 
glioblastomas. Moreover, most secondary glioblastomas were classified as proneural. These findings 
suggest that some of the primary glioblastomas might arise from a clinically silent and undetected 
lower grade astrocytoma, or perhaps more likely, from a neural progenitor cell that can give rise 
either to a lower grade astrocytoma or the proneural type of primary glioblastoma. These data may be 
important in future trials when testing novel treatments for glioblastoma, and they may also aid at 
developing of multigene predictors for assessing the outcome of patients diagnosed with glioblastoma 
(Colman et al. 2010). 
 
Although IDH mutations may be one of the initiating events in the molecular pathogenesis of many 
secondary glioblastomas and lower grade astrocytomas, the subsequent molecular events that lead to 
the development of either astrocytic or oligodendrocytic tumors likely require activation of distinct 
cell signalling pathways. This thesis presents a hypothesis that amplifications of KIT, PDGFRA and 
VEGFR2 are more common in secondary glioblastoma and anaplastic astrocytoma than in 
astrocytoma, oligoastrocytoma and oligodendroglioma (III). KIT expression is rare in lower grade 
gliomas, but was it was associated with KIT amplification in recurred gliomas (III). The probability of 
a tumour to acquire amplification of PDGFRA, KIT and VEGFR2 may increase with tumour 
progression, and an amplicon containing these genes may thus be found more frequently at the time 
of tumour recurrence as compared to the first diagnosis of glioma, and more frequently in higher 
grade tumors than in lower grade tumors. These data are in line with the general hypothesis that gene 
amplifications are frequent molecular alterations of later stage tumors (Lengauer et al. 1998). 
Presence of gene amplifications in lower grade diffuse gliomas might suggest that these tumors are 
more malignant than the mere histopathology implies (Riemenschneider et al. 2010). 
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KIT, PDGFRA and VEGFR2 have all been linked with angiogenesis. VEGFR2 is a key proangiogenic 
receptor tyrosine kinase (as discussed in 1.4 above) and PDFGR is involved with pericyte recruitment 
(Pietras et al. 2003). SCF may be produced in glioblastoma as a response to hypoxic conditions, 
possibly by hypoxic perinecrotic glioblastoma cells (Sihto et al. 2009). SCF may enhance endothelial 
cell survival, cell migration and tube formation, and SCF and KIT may thus have a role in tumour 
angiogenesis (Matsui J et al. 2004, Sihto et al. 2007, Sun L et al. 2004). Endothelial proliferation is a 
hallmark of glioblastoma, and a number of clinical trials addressing a variety of anti-angiogenic 
agents are currently underway in the treatment of both newly diagnosed and recurrent glioblastoma 
(Ahluwalia et al. 2010). KIT, PDGFRA and VEGFR2 expression was not significantly associated with 
the neural stem cell markers nestin and prominin, and they were not associated with TP53 mutations 
(III) or p53 expression (II). 
 
Pilocytic astrocytomas lack many of the molecular alterations that are frequently present in adult 
gliomas such as IDH1 and IDH2 mutations (IV, Haapasalo et al. 1999, James & Collins 1992, Ohgaki 
et al. 1993 Ransom et al. 1992 von Deimling et al. 1994, Yan et al. 2009). Tandem duplications at 
7q34 resulting in a BRAF fusion gene with constitutive BRAF kinase activity are frequent in pilocytic 
astrocytoma, whereas this alteration does not occur in higher-grade gliomas (Jones DT et al. 2008). In 
line with these findings, we found that pilocytic astrocytomas do not usually have amplifications of 
KIT. We found instead that in pilocytic astrocytomas tumour endothelial cells frequently express KIT 
and SCF and that endothelial KIT was often phosphorylated (IV). In pilocytic astrocytomas, and 
possibly in ependymomas, endothelial cell KIT expression was associated with a young age at the 
time of the diagnosis (IV). Yet, juvenile pilocytic astrocytomas are usually associated with good 
prognosis (Ohgaki H & Kleihues P 2005a) and are not necrotic, and data from glioblastoma patient 
series suggest that glioblastomas with moderate to strong KIT expression in the tumour endothelial 
cells may be associated with favourable outcome as compared to tumors with little KIT expression 
(Sihto et al. 2009). Therefore, other factors, such as the degree of maturation of the vascular system 
might be associated with endothelial cell KIT expression in young individuals with pilocytic 
astrocytoma.  
 
Further studies on the topic of this thesis should address the relationships between EGFR, KIT, 
PDGFRA and VEGFR2 alterations and the newly discovered IDH mutations and NF1 mutations. 
Very recently in sonic hedgehog medulloblastomas a phenomena of massive chromosome 
rearrangements in a one-step, catastrophic event termed chromothripsis has been characterized. 
Cromothripsis can lead to gene amplifications and, the association of chromothripsis with TP53 
mutations links the phenomena to more complex caryotype form of acute myeloid leukemia and poor 
survival (Rausch et al 2012). In higher grade gliomas with gene amplifications, it would be interesting 
to see if all RTK gene amplifications are equal and if more complex caryotypes with poorer outcomes 
can be identified. 
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Endothelial cell KIT expression also requires further study, since this might be a potential treatment 
target. The emerging new molecular classification of astrocytic brain tumors may provide a new basis 
for future clinical trials, since this may allow improved patient selection for targeted agents, although 
the marked heterogeneity of glioblastoma, in particular, may turn out to be a difficult obstacle to 
overcome. Diffusively growing glial tumors are difficult to cure by surgery, they are only moderately 
sensitive to irradiation and conventional chemotherapy, and targeted therapies have thus far not 
resulted in impressive results in the treatment of these tumour types. Therefore, further studies on the 
molecular pathogenesis of gliomas continue to be of critical importance.      
 
CONCLUSIONS 
 
The aims of the present thesis was to study EGFR mutations and their association with EGFR 
amplifications in various histological types of human cancer, including brain tumors (I); to investigate 
the amplifications of KIT, PDGFRA, VEGFR2 and EGFR genes and their mutations in glioblastoma 
(II); to investigate amplifications of KIT, PDGFRA, VEGFR2 and EGFR genes in low grade glioma, 
anaplastic astrocytoma and their recurrences (III); to evaluate KIT and VEGFR2 expression in 
endothelial and tumour cells in paediatric brain tumors and to investigate KIT gene copy numbers in 
these tumors (IV); and finally to study the heterogeneity of EGFR and KIT gene amplification and 
their protein products in gliomas and glioblastoma (V). We conclude that  
 
1. Apart from the deletion mutant EGFRvIII in glioblastoma, EGFR mutations appear rare in human 
brain tumors. No mutations were found in EGFR exons 18, 19 and 21 that encode the kinase part of 
the EGFR receptor tyrosine kinase in brain tumors. Mutations in EGFR resulting in an aberrant kinase 
domain occur, however, in adenocarcinomas and bronchioloalveolar carcinomas of the lung.  
 
2. EGFR gene amplification is common in primary glioblastoma, and was present in 70% of the 
glioblastomas investigated. EGFR protein is commonly expressed in glioblastoma and it is frequently 
activated (phosphorylated). Presence of EGFR amplification is strongly associated with expression of 
phosphorylated EGFR. KIT, PDGFRA and VEGFR2 genes are also frequently amplified in primary 
glioblastoma (KIT in approximately 50% of the cases, and PDFRA and VEGFR2 in approximately 
one third of the cases). 
 
3. Amplifications of KIT, PDGFRA, VEGFR2 and EGFR genes occur occasionally in lower grade 
gliomas (astrocytomas, oligodendrogliomas, oligoastrocytomas and anaplastic astrocytomas), but 
generally at a lower frequency than in glioblastoma. KIT and PDGFRA amplifications are more 
common in anaplastic astrocytomas than in astrocytomas, oligodendrogliomas and oligoastrocytomas. 
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KIT amplification is more frequent in recurrent lower grade gliomas and secondary glioblastomas as 
compared to newly diagnosed lower grade gliomas.  
 
4. Paediatric pilocytic astrocytomas usually neither harbour amplifications of KIT nor express the KIT 
protein. Instead, KIT expression is common in the tumour endothelial cells, and endothelial cell KIT 
was frequently phosphorylated. Expression of endothelial cell KIT in pilocytic astrocytoma is 
associated with a young age at the time of the diagnosis. Ependymomas also frequently express KIT 
in endothelial cells, and endothelial cell KIT expression tends to be associated with young age at the 
time of the diagnosis.  
 
5. Glioblastomas may show heterogeneity with respect of EGFR and KIT amplifications. The degree 
of heterogeneity in tumour KIT amplification may be greater than that of EGFR, which showed only 
limited heterogeneity between several tissue samples analyzed from one tumour. Expression KIT and 
phospho-KIT proteins were also markedly heterogeneous in glioblastomas, and heterogeneous 
expression of KIT and EGFR proteins was found also in astrocytomas and anaplastic astrocytomas.  
 
Taken together, these findings support an important role for EGFR in the molecular pathogenesis of 
many primary glioblastomas. The importance of KIT, PDGFRA and VEGFR2 amplifications in 
glioma molecular pathogenesis seems less evident, and these alterations might often be secondary 
events related to glioma progression. The role of KIT may be multifunctional, and one of the roles 
may be associated with glioma angiogenesis. None of these receptor tyrosine kinases has thus far 
turned out to be a viable therapeutic target in clinical trials.  
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